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Neurodevelopmental risks for Bipolar Disorder 
David Freedman 
 
 This dissertation aims to add to the growing literature on the risks and mechanisms in early life 
that may be associated with later bipolar disorder (BP), expanding the understanding of when and why 
divergences from typical developmental course occur in BP, if they do. To do so, it utilizes prospectively 
obtained, serologically documented prenatal biomarkers and clinically documented prenatal and perinatal 
risk factors, as well as premorbid measures of neurocognitive functioning, in a well-defined birth cohort 
followed up for BP. This offers a unique opportunity to test some of the evidence as to whether BP is a 
neurodevelopmental illness. The first paper is a systematic literature review of the neurodevelopmental 
hypothesis of BP. This review focuses on three developmental time points: prenatal and perinatal 
exposures, premorbid and prodromal symptom development, and neurocognitive functioning prior to 
onset. The second paper focuses on two specific putative prenatal and perinatal risk factors for BP: T. 
gondii and oxytocin to induce labor. The third paper assesses cognition, using both the BP case-control 
study and the full birth cohort to assess risks for BP and the potential that cognitive impairment reflects a 
mediator or endophenotype of later BP. Taken as a whole, the findings suggest support for the 
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Introduction and overview 
 Bipolar disorder (BP) and schizophrenia (SZ) are serious mental illnesses which disrupt and 
impair social, behavioral, familial, and occupational functioning, being among the largest contributors to 
years lost to disability globally (Vos, Flaxman et al. 2012). Although diagnostically specific, BP and SZ are 
frequently hypothesized to be closely related, sharing phenotypic symptoms, genetic, and environmental 
risks, and perhaps constituting different specific manifestations of similar etiologies. Both conditions are 
often viewed as neurodevelopmental diseases, despite the evidence underlying this hypothesis being 
stronger for SZ than for BP. Whether BP is a neurodevelopmental disease, and whether conceptualizing 
it as such helps to elucidate the causes, mechanisms, trajectories, and possibilities for prevention, is a 
complex question and the answers remain elusive.  
 The neurodevelopmental approach to the origin and course of SZ and BP holds promise for 
better outcomes because it searches for the causes and mechanisms which result in illness later in life, 
opening the potential for earlier and more effective intervention and prevention. As suggested by Insel, 
the neurodevelopmental approach identifies stages of disease progression, each of which may offer 
specific types of intervention and prevention (Insel 2010). Another way to ask this question is: during 
which periods do the divergences from typical developmental course occur, and why have they occurred? 
The neurodevelopmental hypothesis suggests that the divergences may begin before conception and that 
the risk for them continues through illness onset, at least. For each symptom cluster which constitutes the 
diagnostic criteria for illness, the timing and mechanism of divergence offers the potential for prevention 
or remediation. In order to identify the interventions and preventive steps that might work, further research 
on the antecedent risks, mechanisms, and causes is needed. This is especially true for BP, about which 
many fewer rigorous, population based studies have been conducted. Because of neurodevelopmental 
and symptom similarities, one potential approach to better understanding BP is to use the evidence and 
hypotheses developed to understand SZ, and test whether the purported etiologies and mechanisms are 
similar, or not, to BP. 
 A number of competing hypotheses about the relationship between BP and SZ have been 
proposed (Trede, Salvatore et al. 2005, Craddock and Owen 2010, Demjaha, MacCabe et al. 2012, 
Derks, Allardyce et al. 2012). Craddock and Owen have argued that the Kraepelinian dichotomy, which 
   
2 
 
postulated BP and SZ as categorically distinct forms of psychosis, is not supported based evidence of the 
similarities in genetic risk and pathogenic mechanisms; they articulate a dimensional disease hypothesis 
that would consider SZ and BP along a psychotic disorder spectrum, more similar than distinct, but 
clinically differentiated nonetheless (Craddock and Owen 2010). They suggest that the differences along 
this psychosis-mood continuum are idiosyncratic individual variation rather than associated with a causal 
mechanism. Demjaha, MacCabe and Murray, offer a similar view of the underlying genetic risk shared by 
both illnesses which supports the relationship between the conditions; they go on, however, to suggest 
that the disorders diverge because of additional genetic and environmental exposures which more 
substantially impair neurodevelopment for those who later develop SZ than those who develop BP 
(Demjaha, MacCabe et al. 2012). The distinction in this formulation from Craddock and Owen's is that the 
variation is identifiable beyond the normal individual idiosyncratic manifestation of disease.  
 In contrast to these views of BP and SZ being diagnoses along a psychotic disease continuum, 
Derks et al., using latent class analysis, report quite good class specificity for SZ, but symptom 
heterogeneity for BP, suggesting the illnesses are distinct, but that the BP category may be less discrete. 
They suggest this heterogeneity may explain the overlap of genetic risk for SZ and BP (Derks, Allardyce 
et al. 2012). In further support of categorization, a recent editorial by Carpenter summarized a 
clinician/researcher view of these disorders, stating: "The modest progress made to date has not been 
sufficient to redefine the classification landscape based on neurobiology, biomarkers, or distinctive 
phenomenology. One winces when an overlap is claimed based on similar ratings on a particular test at a 
single assessment, because this simplistic analysis overlooks the remarkable distinctions in form and 
content between these disorders" p961 (Carpenter 2013). 
 Nevertheless, the comparative lack of research on the antecedents of BP makes such 
hypotheses difficult to parse; with limited evidence regarding the risks, mechanisms, and phenotypic 
specificity of BP, it is not possible to know how BP relates to SZ. For instance, despite significant 
attention to putative shared genetic risks (Consortium 2013), evidence suggests pleiotropic effects of 
genes relating to psychiatric illnesses (Sivakumaran, Agakov et al. 2011). Along with the direct causal 
hypothesis of environmental risks, these pleiotropic genetic effects which may result in distinct diagnoses 
support the need more complete and complex investigation of the environmental risks and the 
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interactions between genetic and environmental risks. This is particularly important for BP, about which 
less is known regarding the antecedent risks.  
 BP is characterized by significant changes in mood, and defined by (hypo)mania interspersed 
with major depressive episodes (Goodwin, Jamison et al. 2007). Manic episodes are distinct periods of 
abnormal and persistent elevated, expansive, or irritable moods. The symptoms of mania may include: 
grandiosity, irritability, paranoia, racing thoughts, greater energy, decreased need for sleep, pressured 
and excessive speech, thought disorder, distractibility, and impulsivity (Goodwin, Jamison et al. 2007). 
Major depressive episodes in BP are similar to those in unipolar affective disorder, marked by alterations 
of mood, cognition, and behavior. Suicide attempts are common in BP (Jamison 2000). These mood 
alterations disrupt social and occupational functioning, and frequently necessitate hospitalization. BP is 
associated with a substantial burden for patients, family members, and society, being the sixth-leading 
cause of time lost to disability or death (Simon 2003). 
 The studies which follow utilize prospectively obtained, serologically documented prenatal 
biomarkers and clinically documented pre- and perinatal risk factors, as well as premorbid measures of 
neurocognitive functioning, in a well-defined birth cohort followed up for BP. This offers a unique 
opportunity to test some of the evidence as to whether BP is a neurodevelopmental illness.  
 
Study Methods 
 The Child Health and Development Study (CHDS) is a large, representative birth cohort, 
containing 19,044 live births, which included nearly all pregnant women receiving obstetric care from the 
Kaiser Permanente Medical Care Plan, Northern California Region (Kaiser) in Alameda County, California 
between 1959 and 1966. (van den Berg 1979, van den Berg, Christianson et al. 1988). This cohort has 
been followed prospectively, with prenatal serologic samples obtained during pregnancies, perinatal 
measures obtained during routine medical care, childhood cognitive assessment performed at ages 5, 9-
11, and 15-17 on subsets of the birth cohort, and psychiatric diagnoses confirmed in adulthood. Using a 
nested case-control design to obtain all BP cases and matched controls from the CHDS birth cohort, this 
research investigates the relationship between serologically obtained prenatal exposures and birth 
complications, early childhood cognition, and onset of BP. Previously, this birth cohort has been 
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extensively studied for prenatal and other early developmental risk factors for SZ, which supports the 




 People with potential DSM-IV BP, which included BP I, BP II, BP NOS, and BP with psychotic 
features, were ascertained by screening procedures which used data from three sources: Kaiser’s 
electronic medical records database, the Alameda County Behavioral Health Care Services (ABHCS) 
database, and a mailing to the entire living CHDS birth cohort (mothers and children). This approach 
sought to maximize ascertainment of individuals with BP. CHDS cohort members who belonged to Kaiser 
when first treated would have been ascertained from this source. Subjects who left Kaiser prior to the first 
treatment of BP and who did not have other health insurance, but who still lived in Alameda County, 
would likely have been treated by ABHCS and therefore ascertained. Subjects who were not ascertained 
by these two approaches were ascertained by a mailed survey to the entire cohort. 
 The ascertainment process identified 448 subjects who potentially met the criteria for BP and 
psychotic disorder. 
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Ascertainment of Kaiser subjects 
 Subjects with potential BP (and other psychotic disorders) were identified by screening Kaiser 
inpatient and outpatient databases. Computerized record linkages between CHDS and Kaiser identifiers 
were conducted on these databases. The inpatient database included all psychiatric hospitalizations of 
Kaiser members regardless of the hospital at which treatment is received. This covered the period from 
1981-2010. Those with discharge diagnoses of ICD-9 295-298 from the Kaiser inpatient database were 
considered as potential BP subjects. A database of outpatient treatment was introduced in 1981, but did 
not contain searchable codes for diagnoses until 1995. Potential BP cases from the outpatient database 
were considered to screen positive if they received ICD-9 diagnoses of 295-298 excluding unipolar major 
depressive disorder. Case ascertainment also used the Kaiser outpatient pharmacy database, which 
commenced in 1992. Cases screened positive based on prescriptions for mood stabilizing medications 
used in the treatment of BP (lithium, carbamazepine, valproic acid). Before contacting subjects who were 
currently enrolled in Kaiser, the subject’s treating psychiatrist was contacted, informed about the study, 
and asked to approve contact with the subject to seek his/her consent to participate. 
 Any subjects identified by these methods were invited to participate in the study, receiving a letter 
to the most recent address, and those who did not refuse contact by returning a postcard, were contacted 
to arrange an appointment for a diagnostic interview. Up to several repeat appointments were scheduled 
for subjects who failed to attend the interview. Extensive efforts were made to locate individuals who were 
no longer living at the most recent listed address, including Department of Motor Vehicles records, 
telephone directories, and contacting the subjects’ parents or siblings from CHDS or Kaiser files. Mortality 
records, reverse directories, jail searches, and visits to previous addresses were also used as necessary.  
 
Ascertainment by Alameda County Behavioral Health Care Services (ABHCS)  
 Outpatients with potential BP were also ascertained by electronic record linkage between the 
CHDS and ABHCS identifiers. The ABHCS database included treatment from 1993-2009. These subjects 
screened positive based on ICD-9 outpatient diagnoses of 295-298, excluding unipolar major depressive 
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disorder. Procedures for finding and recruiting these potential subjects were similar to those described 
above for ascertainment by Kaiser. 
 
Ascertainment of CHDS birth cohort by mailed questionnaire and follow-up 
 The third method of ascertainment was initiated by letters mailed to all living mothers (N=6,971) 
and cohort members (N=13,009) with known addresses in the entire CHDS cohort (excluding families in 
which potential cases had already been identified in the Kaiser and/or ABHCS) along with a questionnaire 
on mental and physical health. This was conducted from 2009-11. Questionnaire respondents who 
reported “mental health problems” in an eligible cohort member (including the respondent him or herself) 
were contacted by a trained Kaiser study interviewer who administered the Family Interview for Genetic 
Studies (FIGS) to screen for possible BP or psychotic illness in the cohort member. If the FIGS indicated 
at least one bipolar and/or psychotic symptom (delusions/hallucinations), then the cohort member was 
considered to have screened positive, and was invited to participate in the diagnostic interview.  If the 
respondent (mother or sibling) described symptoms in a birth cohort member, the respondent was asked 
if he or she would be willing to have the study contact the affected family member about participation in 
the study. If the respondent agreed, the affected cohort member was contacted by letter and invited to 
participate.   
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 Accurate diagnosis of BP is critical to understanding its causes. A number of prior studies have 
suffered from poor diagnostic specificity of BP, grouping a number of illnesses into catch-all categories 
such as “affective disorders.” The current research benefits from the careful diagnostic assessment and 
inclusion of confirmed cases of BP.  
 A total of 214 subjects (48% of those ascertained) were interviewed using the Structured Clinical 
Interview for DSM-IV TR (SCID). The reasons that some subjects were not interviewed were: 100 could 
not be contacted, 80 refused or failed to keep the appointment, and 54 who could not be interviewed 
because he or she had died, were incarcerated, permission from the physician could not be obtained, or 
because the person was too psychotic or mentally disabled.  
 Study interviewers had a minimum of a master’s degree in a mental health field and were trained 
to reliability on the SCID. DSM-IV-TR diagnoses including diagnostic qualifiers representing subtypes of 
BP were systematically assigned by consensus of three experienced clinicians (psychiatrists/Ph.D. 
psychologist), based on review of the SCID and medical records. This yielded 72 BP cases. Among those 
interviewed, consensus diagnoses of non-BP disorders were also assigned: there were 61 cases of SZ 
and other schizophrenia spectrum disorders, 62 cases of major depressive disorders, and 19 cases with 
other diagnoses. These non-BP categories were not included in the present study. Although unipolar 
major depressive disorder was not included in the screening procedure, the diagnostic protocol enabled 
us to exclude subjects with database diagnoses of BP and/or psychotic disorders who were found instead 
to have unipolar depressive disorder in accord with structured research criteria. 
 Comparing the interviewed to those not interviewed demonstrates few differences (Table 1). 
Although both maternal and paternal age differ, the amount of difference in mean age is 2 years for 
fathers and 1 year for mothers. Similarly, gestational age differs by 4 days. These differences are likely 
statistically but not clinically significant. No differences exist on the exposures of interest for this study. 
  




   
Table 1: Characteristics of potential case subjects interviewed and not interviewed. 







Maternal age, mean years (SD) 27.7 (6.7) 26.5 (6.5) 0.055 
Paternal age, mean years (SD) 32.2 (7.7) 30.1 (7.5) 0.007 
Maternal race, N (%)   0.479 
White 119 (55.9) 118 (51.1)  
Black 76 (35.7) 87 (37.7)  
Other 18 (8.4) 26 (11.2)  
Maternal education, N (%)   0.750 
Less than high school 47 (24.2) 52 (25.2)  
High school graduate 76 (39.2) 86 (41.8)  
Some college/college graduate 71 (36.6) 68 (33.0)  
Gestational age, mean days (SD) 282.5 (17.7) 278.6 (19.5) 0.027 
Any maternal psychiatric history, N (%)   0.731 
Yes 21 (10.1) 25 (11.1)  
No  188 (90.0) 201 (88.9)  
Maternal smoking   0.476 
Yes* 81 (46.0) 83 (42.4)  
No 95 (54.0) 113 (57.7)  
Exposure to gestational influenza   0.832 
Exposed 13 (6.4) 13 (5.9)  
Unexposed 190 (93.6) 207 (94.1)  
Childhood Raven number tested (mean)  105 (-0.2) 97 (-0.11) 0.497 
Childhood Peabody number tested (mean)  107 (96.68) 97 (97.79) 0.624 
Induced labor   0.909 
Induced 7 (3.4) 7 (3.4)  
Not induced 98 (48.0) 92 (45.1)  
*current smoking or smoked until current pregnancy 
 
 Nevertheless, as with all longitudinal studies, loss to follow-up potentially biases this study. The 
ascertainment process was conducted to capture as many potential cases as possible and every effort 
was made to locate and interview each. While few meaningful demographic differences were observed, it 
is not possible to calculate the extent to which bias from loss to follow-up might be having an effect or the 
direction of that hypothetical effect. It is important to note, however, that the prevalence of BP cases 
identified in this study comports with the national and international rates (Merikangas, Akiskal et al. 2007, 
Merikangas, Jin et al. 2011), providing some confidence that few cases have been missed. Moreover, 
because of the extensive contemporaneous documentation and longitudinal follow-up, information about 
the exposed in the full cohort makes direct assessment of potential bias in ascertainment testable. This is 
an important strength of this study.  
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Ascertainment from PDS I study 
 Additional cases of BP had been ascertained through Kaiser records by an earlier study (Prenatal 
Determinants of Schizophrenia I, PDS I) and were included in the present study (Susser, Schaefer et al. 
2000). Although the purpose of PDS I was to identify SZ and other schizophrenia spectrum disorder 
cases, BP cases were also diagnosed by interview in that study. The protocol for the PDS I included the 
same electronic linkages with the Kaiser inpatient, outpatient, and pharmacy databases, and utilized the 
same ICD-9 diagnostic codes (295-298). Ascertainment covered the period from 1981-1998. The only 
other differences in the screening methods are that the PDS I did not include review of pharmacy records 
for treatment with mood stabilizers, and the PDS I included a second screening step, which involved 
psychiatrist review of abstracted data from inpatient/outpatient records for symptoms of psychosis. The 
Diagnostic Interview for Genetic Studies (DIGS), rather than the SCID, was used for interviewing potential 
subjects in the PDS I. There were 23 BP cases diagnosed in the PDS I study.  
 In total, then, 95 people with BP were diagnosed following ascertainment from all sources and 
clinical interview.  
 After complete description of the study to the subjects, written informed consent was obtained. 
The study protocol was approved by the Institutional Review Boards of the New York State Psychiatric 
Institute and Kaiser.  
 
Control Selection 
 In order to ensure that controls would have been equally likely (as their matched cases) to be 
ascertained if they had been treated for BP in Kaiser or ABHCS, controls were matched to cases on 
membership in Kaiser (for cases ascertained through Kaiser records) or residence in Alameda County 
(for cases ascertained through ABHCS or by CHDS mailing survey) in the year the case was first treated 
as reported in the SCID. For Kaiser, membership in the plan at that time was used for control matching, 
since cohort members would have been documented in Kaiser databases if they sought care for BP. The 
DMV was used to ensure place of residence at the time of diagnosis for cases treated by ABHCS and 
those identified from the mailed survey, since these subjects would have been the population at risk for 
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treatment at same time. The vast majority of the subjects who received the mailing were Alameda County 
residents. 
 Control matching criteria included: date of birth (+/- 30 days), sex, and availability of maternal 
archived sera (for serologic studies). A maximum of an 8:1 ratio of controls to cases was achieved, as it 
represented the maximum number of controls that could be successfully matched to cases on all criteria 
and to maximize statistical power. 
 Exclusion criteria (prior to matching) were: all of the CHDS cohort members who screened 
positive for BP or psychotic disorders, but did not have BP (N=376) and siblings of cases; potential 
controls who belonged to Kaiser at the time of case ascertainment were excluded from the control pool 
for cases identified from ABHCS or the cohort mailing; and siblings of selected controls were excluded 
from further control selection, so that all controls were independent observations, each representing a 
single family or pregnant woman.   
 This protocol yielded 754 matched controls. As can be seen below in table 2, cases and controls 
differ on maternal race, with fewer white controls and more "other" controls. As expected, cases and 
controls differ on having a family history of psychiatric illnesses.  
 
Table 2: Demographic comparison of cases and controls 
 Bipolar Cases  
(N = 94) 
Controls  
(N = 746) 
P value 
Maternal age at child's birth, Mean (SD) 27.3 (6) 28.0 (6) 0.32 
Maternal education, N (%)   0.85 
< High school 18 (21) 128 (19)  
High school graduate 32 (37) 271 (39)  
Some college or college graduate 36 (42) 293 (42)  
Maternal race, N (%)   0.07 
white 64 (69) 425 (58)  
African-American 24 (26) 215 (29)  
other 5 (5) 92 (13)  
Paternal education N (%)   0.51 
< High school 12 (14) 134 (20)  
High school graduate 26 (32) 192 (28)  
Some college or college graduate 44 (54) 350 (52)  
Paternal race, N (%)   0.14 
white 55 (70) 387 (59)  
African-American 19 (24) 189 (29)  
other 5 (6) 79 (12)  
Maternal psychiatric history (any), N (%) 24 (25) 132 (18) 0.07 
Birthweight in grams, Mean (SD) 3374 (21) 3289 (17) 0.17 
Gestational age in days, Mean (SD) 281 (16) 280 (14) 0.33 
 
   
13 
 
 The decision to exclude siblings and those who screened positive from the pool of people eligible 
to be controls, may have made the controls healthier than they otherwise should have been. It is unlikely 
that this had a significant effect because the matching process and very large birth cohort makes 
selection of any particular member of the cohort as a control unlikely. Not surprisingly, those who 
screened positive but do not have BP, differ from the controls, as can be seen in Table 3, on a number of 
outcomes of interest. Those who screened positive perform more poorly on cognitive testing, have lower 
maternal education, and are more likely to be African-American. They are also somewhat, although not 
statistically significantly, more likely to have been exposed to oxytocin and to gestational influenza.  
 
Table 3: Comparing percent exposed for 376 screened positive but not BP and potential controls: 
 Exposed / 
ascertained 
Exposed / potential 
control 
Exposed percent 
of total cohort 
p-value 
Oxytocin to induce  0.056 % 0.041 % 0.0011 % 0.15 
Gestational flu 0.061 % 0.043 % 0.0012 % 0.098 
Maternal race, African American  0.451 % 0.241 % 0.0078 % 0.0001 
Maternal education, some 
college or college graduate 
0.335 % 0.431 % 0.0069 % 0.0001 
Raven (N = number tested) 165 6894  .0073 
PPVT (N = number tested) 167 6835  .001 
 
 One way to estimate how much, or if, this mattered for the study results, is to assume that ten 
percent of the excluded subjects had met the matching criteria and been selected, ignoring the matching 
process, and assuming a simple equal probability of being selected. These assumptions overestimate the 
approximately six percent of the cohort who met criteria to be controls, as well as overestimating the 
probability that any single individual would be selected because the matching criteria limited the 
probability for most cohort members. Nevertheless, these assumptions are conservative in the sense of 
being likely to over-weight the importance of the exclusion. These assumptions would have added 
approximately 35 subjects to the control pool for possible selection, making the total number of controls 
781.  
 Using the population prevalence rate of each exposure and outcome, this would add 7 people 
with less than high school graduation, 13 who completed high school, and fifteen with some college or a 
college degree; it would add 23 white, 8 African-American, and 4 people of other race/ethnicity to the 
controls; for oxytocin to induce labor, which has a population prevalence of 0.0415 in this birth cohort, it 
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would increase the number of exposed controls by 2 people; and for gestational influenza, with a 
population prevalence of 0.0432, it would increase the number of exposed controls by 2 people.  
 Because T. gondii was measured by testing of maternal sera as described below, it was not 
possible to calculate the population prevalence precisely for this birth cohort because only sera for cases 
and selected controls were analyzed. Seroprevalence of T. gondii antibody in controls was estimated at 
18 percent for the selected controls in the case-control study which would add six exposed controls. 
Based on chi-square comparisons of these hypothetical adjustments, none of the changes in the numbers 
of exposed controls alters the observed effects. 
 
Summary of background and significance 
 Despite being identified as distinct but related conditions, research on the antecedent risks for SZ 
has been more substantial than the antecedents of BP. Further investigation of BP and its putative 
causes, onset, and course has the potential to improve the understanding of similarities and differences 
between SZ and BP, and to identify mechanisms and potential etiologies, all with the aim of improving 
prevention and intervention. Whether BP is most appropriately considered a neurodevelopmental disorder 
remains debated, as does the exact nature of the onset and course of illness. Yet, the accumulating 
evidence tends to support the hypothesis that it is neurodevelopmental, has premorbid and prodromal 
phases, and likely has antecedent risks. Additional testing of this hypothesis, using more rigorous 
methodological designs, has the potential to advance the understanding of an illness which has 
significant social and personal costs, making the studies which follow a unique and significant contribution 
to understanding BP. 
 
Prior studies from the CHDS birth cohort  
 Ideally, testing of the neurodevelopmental hypothesis of BP requires a longitudinally followed 
birth cohort with prenatally and perinatally obtained evidence of potential risks, as well as continual follow-
up testing during the developmental period and confirmed diagnosis in adulthood. Few, if any, prior 
studies have had such complete data available. The CHDS was an NIH-sponsored study of nearly 20,000 
pregnancies in women enrolled in the Northern California Region of the Kaiser Permanente Medical Care 
Plan (van den Berg 1979). Pregnancy, labor and delivery, and child development data were obtained 
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prospectively. In addition, prenatal maternal serum specimens were obtained during each trimester and 
stored frozen for later use. The relationship between elevated T. gondii IgG antibody titer and risk for SZ 
was examined previously in the CHDS (Brown, Schaefer et al. 2005). That study ascertained cases from 
computerized records, chart review, and diagnostic interview, similar to the method used in this study. 
Maternal sera were assayed using the same technique as well. Seventy-one case subjects were 
identified and controls were matched on availability of sera, date of birth, and enrollment in the health 
plan. Controlling for maternal age, the only covariate found to potentially confound the association, the 
adjusted odds ratio for SZ for those with a high IgG titer compared to the reference group (reference 
group: IgG titer <1:16) was 2.61 (95% CI: 1.00, 6.82, p=.051). There was no association between 
moderate IgG antibody titer and risk of SZ (Brown, Schaefer et al. 2005).  
 A comprehensive neuropsychological assessment was administered to subjects identified as 
having developed SZ in the CHDS and who were recruited into the Developmental Insult and Brain 
Anomaly in Schizophrenia Study (DIBS). The DIBS investigated early developmental risks for later 
cognitive impairment in SZ. A total of 50 subjects were administered the comprehensive 
neuropsychological battery (Brown, Vinogradov et al. 2009). Maternal infection, including T. gondii, was 
found to be associated with impaired adult cognitive performance, specifically with measures of executive 
functioning (Brown, Vinogradov et al. 2009). This study suggests a relationship between prenatal infection 
and cognitive impairment observed in adults with SZ. The DIBS neuropsychological testing was also 
analyzed in a trajectory model, using the CHDS Peabody Picture Vocabulary Test (PPVT) administered 
at ages 5 and 9-11 to examine the course of cognitive functioning over 33 years. This study found a ten 
point difference in the early childhood PPVT, with those who would later develop SZ performing more 
poorly than the matched controls. In adulthood, the gap in performance was wider, with those who had 
developed SZ scoring 15 points below the controls (Kremen, Vinogradov et al. 2010). This study supports 
the utility of examining the early childhood test battery administered in the CHDS with later development 
of psychiatric illnesses. 
 Birth complications, while extensively studied, have not been examined in the CHDS in relation to 
SZ or BP, or as antecedents to childhood neurocognitive deficits. 
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Previous studies in the Prenatal Factors and Bipolar Study (PFB) 
 The proposed study uses data obtained in the NIH-sponsored PFB. Previously, a number of 
findings have been published utilizing this study. First, gestational exposure to clinically diagnosed 
maternal influenza has been shown to raise the risk of offspring BP by nearly fourfold, and nearly sixfold 
for BP with psychotic features (Parboosing, Bao et al. 2013). In addition, using maternal serum drawn 
during pregnancy to directly quantify maternal influenza, the association between gestational influenza 
and later life BP with psychotic features was fivefold and the association with BP without psychotic 
features was non-significant (Canetta, Bao et al. 2014). This result is similar to the findings in the CHDS 
cohort that maternal influenza during the first half of pregnancy increases the risk of SZ by a factor of 
three (Brown, Begg et al. 2004). 
 Paternal age has also been found to increase the risk for SZ, including in the CHDS (Brown, 
Schaefer et al. 2002). A study in the PFB found no increased risk for BP associated with paternal age, 
controlling for maternal age (Brown, Bao et al. 2013). Treating paternal age as a continuous variable, no 
association was observed with BP (OR=1.00, 95% CI=0.97-1.04, p=0.83), and this did not meaningfully 
change when controlling for maternal age (OR=1.03, 95% CI=0.98-1.08, p=0.29). One prior study found 
maternal age associated with an increased risk of BP, although it became attenuated when controlling for 
paternal age (Menezes, Lewis et al. 2010). This was also tested in the PFB. Again, no association was 
observed between maternal age and BP (OR=0.98, 95% CI=0.95-1.02, p=0.31), and controlling for 
paternal age did not alter this result (OR=0.96, 95% CI=0.90-1.02, p=0.16).  
 Finally, maternal smoking was also analyzed in the PFB for its potential association with BP 
(Talati, Bao et al. 2013). Smoking during pregnancy was associated with a twofold increased risk for BP 
for offspring (OR=2.03; 95% CI 1.20-3.45; p= 0.01), and this finding was essentially unchanged when 
adjusting for a number of potential confounders, including maternal history of psychiatric illness, maternal 
alcohol use during pregnancy, and offspring birth weight. 
  






 What follows are three papers. First, I present a systematic literature review of the 
neurodevelopmental hypothesis of BP. This review focuses on three developmental time points: prenatal 
and perinatal exposures, premorbid and prodromal symptom development, and neurocognitive 
functioning prior to onset. The second paper focuses on two specific putative prenatal and perinatal risk 
factors for BP: T. gondii and oxytocin to induce labor. The third paper assesses cognition, using both the 
BP case-control study and the full CHDS cohort to assess risks for BP and the potential that cognitive 
impairment reflects a mediator or endophenotype of later BP.  
 These studies aim to add to the growing literature on the risks and mechanisms in early life that 
may be associated with later BP, expanding the understanding of when and why divergences from typical 
developmental course occur in BP, if they do. As with any small set of studies, they will not fully answer 
the question of whether BP should be thought of as a neurodevelopmental illness. Negative findings do 
not rule out the possibility of early life divergences, just as positive findings are not enough to opine that 
the divergences are causal of later life BP. Nevertheless, treatment interventions to shift the course of 
illness, and prevention of illness, may all be better informed and targeted, even if incrementally, based on 
the elucidation of specific risks and mechanisms for later life BP, and that is the aim of these studies.  
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Paper 1: Systematic literature review of the neurodevelopmental origins of bipolar disorder 
 The neurodevelopmental hypothesis posits that altered, pathological, or delayed maturation of the 
developing brain, long before the manifestation of disease, shifts the neurodevelopmental trajectory, 
followed by later life onset of psychiatric illness (Oneal and Robins 1958, Fish, Shapiro et al. 1965, 
Nasrallah and Weinberger 1986, Murray and Lewis 1987, Meyer and Feldon 2010, Catts, Fung et al. 
2013, Millan 2013). Determining whether BP is best conceptualized as a neurodevelopmental illness has 
implications for prevention, identification, and treatment. The neurodevelopmental approach holds 
promise for better outcomes not simply because it searches for the causes and mechanisms which result 
in illness, but also because it proposes an understanding of the disease course. Writing about SZ, Insel 
recently suggested that the neurodevelopmental approach identifies stages of disease progression, each 
of which may offer specific types of intervention and prevention (Insel 2010). Delays in treatment, 
misdiagnosis, certain treatments (such as antidepressants which may worsen the course of BP), and a 
high risk of suicide during early phases of the illness, are each worsened by delays in illness identification 
(Howes and Falkenberg 2011). If the neurodevelopmental hypothesis is supported, it suggests that earlier 
identification and intervention may be possible, targeting the specific points of disease progression prior 
to onset.  
 Determining whether BP is a neurodevelopmental disease necessarily requires rigorously 
identifying and differentiating its symptoms from related or similar conditions. BP is characterized by 
significant changes in mood, and defined by (hypo)mania interspersed with major depressive episodes 
(Goodwin, Jamison et al. 2007). Manic episodes are distinct periods of abnormal and persistent elevated, 
expansive, or irritable moods. The symptoms of mania may include: grandiosity, irritability, paranoia, 
racing thoughts, greater energy, decreased need for sleep, pressured and excessive speech, thought 
disorder, distractibility, and impulsivity (Goodwin, Jamison et al. 2007). Major depressive episodes in BP 
are similar to those in unipolar affective disorder, marked by alterations of mood, cognition, and behavior. 
Suicide attempts are common in BP (Jamison 2000). These mood alterations disrupt social and 
occupational functioning, and frequently necessitate hospitalization. BP is associated with a substantial 
burden for patients, family members, and society, being the sixth-leading cause of time lost to disability or 
death (Simon 2003).  
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 International studies suggest that the mean pooled prevalence of BP for six to twelve months is 
approximately .8%, with significant regional differences (Ferrari, Baxter et al. 2011). Lifetime prevalence 
in the United States is estimated at 1.0% for BP I and 1.1% for BP II (Merikangas, Akiskal et al. 2007). 
The onset is typically in the late teens to early twenties (Goodwin, Anderson et al. 2008), although some 
studies have found a second age period of increased occurrence between ages 45 and 54 (Kroon, 
Wohlfarth et al. 2013). Most people with BP experience more than one episode, with the average duration 
of manic and depressive episodes ranging from 4 to 13 months (Goodwin, Jamison et al. 2007). 
 To investigate the strengths and weaknesses of the neurodevelopmental hypothesis of BP, a 
systematic literature was undertaken. This systematic literature review examines whether BP should be 
considered a neurodevelopmental disease similar to how SZ is predominantly viewed. Priority was given 
to papers which use epidemiological approaches, with preference given to population based studies. 
Inclusion criteria were that the paper was written in English and that diagnostic criteria were clearly 
defined. Particular focus has been given to the prenatal and perinatal exposures which have been 
suggested to be associated with psychotic disorders, as well as the measures of cognitive and behavioral 
abilities across time. 
 Searches were conducted in PubMed and Web of Knowledge databases for papers which 
address the neurodevelopmental hypothesis of BP using search terms related to BP. In combination and 
singly, the searched terms included: bipolar disorder, neurodevelopment, manic depress*, psychosis, 
affective disorder, neuropsych*, cognition, trajectory, prenatal, perinatal, obstetric complication, 
prodrome, and premorbid. This produced 2,414 titles, and following deletion of duplicates and review of 
titles and abstracts, 386 papers were considered for inclusion. Additional abstracts were reviewed after 
identification of papers from the reviews and some additional search terms (e.g., oxytocin, T. gondii, 
influenza, parental age, famine, clinical high risk) were hand-searched to check for studies which might 
have been missed. Fifty-seven population based studies were included, with additional reviews, meta-
analyses, patient and clinical studies reviewed for specific questions which arose from, or are 
unanswered by, the population based studies. 
 This review considers four areas relevant to the neurodevelopmental hypothesis: prenatal and 
perinatal risks; whether symptoms mark a distinct period of premorbid and prodromal functioning; whether 
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those at high risk and first episode have diagnostically specific symptoms; and whether cognitive 
processes differ from people without BP.   
 
Overview of literature review 
 In recent years, a great deal of attention has focused on the question of whether or not BP is 
neurodevelopmental, prompting many meta-analyses and reviews focused on potential prenatal, 
perinatal, cognitive, genetic, molecular, and epigenetic roots of BP (Torrey, Miller et al. 1997, Buka and 
Fan 1999, Quraishi and Frangou 2002, Tsuchiya, Byrne et al. 2003, Murray, Sham et al. 2004, 
Krabbendam, Arts et al. 2005, Daban, Martinez-Aran et al. 2006, Robinson and Ferrier 2006, Scott, 
McNeill et al. 2006, Torres, Boudreau et al. 2007, Arts, Jabben et al. 2008, Goodwin, Martinez-Aran et al. 
2008, Bora, Yucel et al. 2009, Kurtz and Gerraty 2009, Tenyi, Trixler et al. 2009, Bora, Yucel et al. 2010, 
Bora, Yucel et al. 2010, Pukrop and Klosterkotter 2010, Skjelstad, Malt et al. 2010, Beblo, Sinnamon et 
al. 2011, Bora, Yucel et al. 2011, Howes and Falkenberg 2011, Howes, Lim et al. 2011, Lewandowski, 
Cohen et al. 2011, Mann-Wrobel, Carreno et al. 2011, Sole, Martinez-Aran et al. 2011, Brietzke, Mansur 
et al. 2012, Depp, Mausbach et al. 2012, Fusar-Poli, Deste et al. 2012, Fusar-Poli, Howes et al. 2012, 
Gigante, Bond et al. 2012, Arango, Fraguas et al. 2013, Bourne, Aydemir et al. 2013, Lim, Baldessarini et 
al. 2013, Martin and Smith 2013, Narayan, Allen et al. 2013, Noto, de Souza Noto et al. 2013, Olvet, 
Burdick et al. 2013, Samame, Martino et al. 2013). These reviews and meta-analyses are discussed 
below.  
 Many of these reviews include studies with disparate diagnostic or outcome criteria, small 
samples, and methodological limitations. As is often the case, many of the studies of putative risks for BP 
are cross-sectional or patient derived samples. Yet, a number of population based studies have been 
conducted as well (Gershon, Hamovit et al. 1987, Lasch, Weissman et al. 1990, Brown, Susser et al. 
1995, Machon, Mednick et al. 1997, vanOs, Jones et al. 1997, Hultman, Sparen et al. 1999, Brown, van 
Os et al. 2000, Jones and Tarrant 2000, Cannon, Caspi et al. 2002, Reichenberg, Weiser et al. 2002, 
Mortensen, Pedersen et al. 2003, Zammit, Allebeck et al. 2004, Tiihonen, Haukka et al. 2005, Pedersen 
and Mortensen 2006, Laursen, Munk-Olsen et al. 2007, Osler, Andersen et al. 2007, David, Zammit et al. 
2008, Kravariti, Reichenberg et al. 2009, Khashan, McNamee et al. 2011, Mortensen, Pedersen et al. 
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2011, Jansen, Magalhaes et al. 2012, Sorensen, Saebye et al. 2012, Class, Abel et al. 2013, Haukvik, 
McNeil et al. 2013, Seidman, Cherkerzian et al. 2013). These studies are also discussed below. 
 
Review of the neurodevelopmental hypothesis for BP 
 Historically, BP has been thought to be related closely to SZ, as noted above, and as the 
neurodevelopmental hypothesis of SZ has become increasingly accepted, a similar hypothesis has been 
applied to BP. For instance, a study focused on early identification and treatment of SZ suggested four 
areas in which to asses risk of SZ based on literature reviews: cognitive deficits, affective disturbance, 
school failure, and social isolation (Cornblatt, Lencz et al. 2003). Whether these same areas of risk would 
be observed in BP, or whether a different set of risks during the developmental period should be 
considered, are analyzed based on a systematic literature review on the putative developmental origins of 
BP.  
 BP and SZ are similar in a number of ways, and are frequently hypothesized to be related across 
numerous causes and phenotypic symptoms (Murray, Sham et al. 2004, Demjaha, MacCabe et al. 2012, 
Hall, Smoller et al. 2012). These similarities may suggest that both conditions are neurodevelopmental, 
particularly because the evidence supporting the neurodevelopmental hypothesis of SZ is strong. As 
recent research suggests, the symptom overlap between BP and SZ is quite high and the conditions can 
be difficult to differentiate (Tamminga, Ivleva et al. 2013). 
 First, the age of onset and population prevalence are quite similar (Kessler, Berglund et al. 2005), 
and the premorbid and prodromal periods are often marked by significant neurodevelopmental and 
clinical symptoms (Sanches, Keshavan et al. 2008, Skjelstad, Malt et al. 2010, Howes, Lim et al. 2011). 
Similarly, cognitive impairment is observed premorbidly in both illnesses (Tiihonen, Haukka et al. 2005, 
Goodwin, Martinez-Aran et al. 2008, Hill, Harris et al. 2008, Urfer-Parnas, Mortensen et al. 2010, 
Sorensen, Saebye et al. 2012). These impairments have been documented in the prodrome (Olvet, 
Stearns et al. 2010), as well as at first episode psychosis (Hill, Reilly et al. 2009, Zanelli, Reichenberg et 
al. 2010, Dickerson, Stallings et al. 2011), and during the course of the illness (Quraishi and Frangou 
2002, Bearden, Woogen et al. 2010), although likely in different domains and with lesser severity in BP 
than in SZ (Seidman, Cherkerzian et al. 2013).  
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 Second, these disorders share a number of important symptoms, with mood symptoms common 
in SZ (Hausmann and Fleischhacker 2002, Siris 2005) and psychotic symptoms common in BP (Ohayon 
and Schatzberg 2002, Merikangas and Lamers 2012). Third, and perhaps related to, or resulting from, the 
overlap in symptomatology, familial aggregation between SZ spectrum disorders and BP has been 
observed (Van Snellenberg and de Candia 2009, Dean, Stevens et al. 2010). The illnesses share 
common genetic risks (Bramon and Sham 2001, Lichtenstein, Yip et al. 2009, Gejman, Sanders et al. 
2011), and have some similar abnormalities in grey and white matter brain structures (Pol, van Baal et al. 
2012). Offspring of a parent with SZ or schizoaffective disorder are at a substantially increased risk for BP 
(Mortensen, Pedersen et al. 2003), and offspring of a person with BP, at an increased risk of SZ (Van 
Snellenberg and de Candia 2009, Dean, Stevens et al. 2010). Finally, treatment with antipsychotic 
medications can be effective for both conditions (Brugue and Vieta 2007, Lieberman 2007, Lieberman 
and Stroup 2011). 
  
Neurodevelopmental hypothesis of BP  
 Four major areas of evidence which are often cited to support the neurodevelopmental 
hypothesis of psychiatric illness are reviewed: prenatal and perinatal risks for later illness, prodromal 
phase symptoms of illness, first episode and onset symptoms of illness, and neurocognitive markers of 
illness.  
 
Prenatal and perinatal risks for BP 
 Population based studies which examine specific, rather than global or aggregated, prenatal and 
perinatal exposures, suggest significantly increased risks for BP (see Table 4). Gestational exposure to 
clinically diagnosed maternal influenza has been shown to raise the risk of offspring BP by nearly fourfold, 
and nearly sixfold for BP with psychotic features (Parboosing, Bao et al. 2013). In addition, using 
maternal serum drawn during pregnancy to directly quantify maternal influenza, the association between 
gestational influenza and later life BP with psychotic features was fivefold and the association with BP 
without psychotic features was non-significant (Canetta, Bao et al. 2014). Assessing affective disorder 
more generally, Sacker et al found an increased risk of illness in a population based birth cohort (N = 32), 
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based on maternal self-report of influenza during pregnancy (Sacker, Done et al. 1995), as did Machon et 
al in a population based ecological study of Helsinki births during an influenza epidemic (Machon, 
Mednick et al. 1997). This association was also observed in the CHDS birth cohort study of SZ, 
 
Table 4: Specific prenatal and perinatal population based studies of BP risk 
Author/year Sample 
size (N) 
Study type Specific prenatal or 
perinatal risk 
Results Significance 




British births during 




















Increased risk of Affective 
disorder with 2nd semester 
exposure to influenza 
compared to controls 
Ecological support for a 
second trimester effect 
of influenza 
Parboosing 
et al (2013) 
92 BP, 722 
controls 
Population based 





Increased risk of BP from 
gestational influenza 
exposure at any time 
during pregnancy  fourfold 
increase in risk of BD (OR 
= 3.82; CI: 1.58, 9.24); and 
an almost 6 times 
increased risk of BP with 
psychotic features (OR = 
5.74; CI: 1.52, 21.7)   




85 BP, 170 
controls 
Population based 





Increased risk of BP with 
psychotic features (OR = 
5.03; CI: 1.38, 18.38), but 
not with BP (OR = 1.26; CI: 
0.65, 2.44) 
Association with BP with 
psychotic features 
Talati et al 
(2013) 
79 BP, 654 
controls 
Population based 





Increased risk of BP 
associated with maternal 
smoking during pregnancy  
(OR = 2.03; CI: 1.20, 3.45) 
Maternal smoking 
assessed prospectively 
at time of pregnancy 
Done et al 
(1991) 
10 BP British population 
based study, births 
March 3-9, 1958 
Preterm birth or 
small for 
gestational age 
Increased risk of Affective 
disorder for shorter 
gestational time 
10 BP cases not 
analyzed, risk is for 32 
Affective disorder cases  
Laursen et 
al (2007) 
814 BP Danish population 
based study, registry 
based 
Preterm birth or 
small for 
gestational age 
Increased risk of BP 5.32 
times (CI: 2.75, 10.72) for 
smallest 10% before week 
37  
Results adjusted for 
age, calendar time, sex, 
family psychiatric 
history, maternal age 





based study, registry 
based, births 1973-
85 
Preterm birth or 
small for 
gestational age 
Increased risk of BP 2.7 
times (CI: 1.6, 4.5); for 
those born 32-6 weeks. 7.4 
times (CI: 2.7, 20.6) for 
less than 32 weeks 
Results adjusted for 
Apgar score, 
birthweight, sex, parity, 











based study, registry 
based, births 1973-
2008 
Preterm birth or 
small for 
gestational age 
Increased risk of 
BP/psychotic disorders for 
continuous measure of 
earlier preterm birth  
Linear relationship: as 
number of weeks in 









British hospital data, 
retrospective patient 
study 
Season of birth Increased risk of BP for 
those born in January 
 






based study,  





Increased risk of BP for 
those exposed in 2nd 
trimester (RR = 1.62; CI: 
1.19, 2.20) 
Ecological study of 
famine exposure 






based study,  




Increased risk of BP for 
those exposed 2nd 
trimester (RR = 1.5; CI: 
Confirmed and 
expanded 1995 study of 
effect of famine 





1944-6 1.19, 1.9); those exposed 
3rd trimester (RR = 1.45; 











Increased risk of BP during 
first trimester war exposure 
(RR = 2.44; CI: 0.996, 
5.99) 















death of close 
relative during 
pregnancy 
Increased risk of Affective 
disorder for male offspring 
following death of close 
relative during 2nd 
trimester (OR = 1.74; CI: 
1.06, 2.84) 
Effect only on male 
offspring; BP not 
analyzed, determined to 
be too rare 
Class et al 
(2013) 
8001 BP Swedish population 






to maternal stress: 
death of close 
relative 
No effect on risk of BP 73 offspring affected by 
maternal loss of relative 
Mortensen 
et al 2003) 
2299 BP Danish population 
based study, registry 
based 
Loss of a parent 
during childhood 
Increased risk of BP 13.6 
times (CI: 11.81, 15.71) for 
first degree relative; 
maternal loss OR = 4.05 








based study, registry 
based, born 1960 or 
later 
Loss of a parent 
during childhood 
Increased risk of BP for 
parental suicide; paternal 
suicide OR = 1.83 (CI: 
1.07, 3.12); maternal 




through age 38; paternal 
suicide is not significant 
by age after controlling 
for covariates 
Appel et al 
(2013) 
555 BP Danish population 
based study, registry 
based, births 1970-
90 
Loss of a parent 
during childhood 
Increased risk of BP when 
loss is due to suicide: male 
offspring HR = 2.0 (CI: 
1.18, 3.39); female 
offspring HR = 2.44 (CI: 
1.56, 3.83)  
Adjusted for age, cohort 
period, family psychiatric 
history 
Clarke et al 
(2013) 
165 BP Helsinki births 1960-
90 
Loss of a parent 
during childhood 
Increased risk of BP 
following loss father or 
sibling before age 5: OR = 
1.6 (CI: 1.1, 2.5)  
Adjusted for age, sex, 










based study, births 
1973-83, registry 
based 
Low birth weight Birthweight, birth length, 
parity, gestational age are 
not associated with BP 
 
Mortensen 




sex, day of 
birth 
Danish population 




HSV1, HSV2, T. gondii, 
CMV are not associated 
with BP 




10 BP 19 year follow-up of 
community sample 
Hypoxia-ischemia Fetal hypoxic ischemia is 









Hypoxia-ischemia History of perinatal 
asphyxia is associated with 
smaller left amygdala in 
people with BP 
Structural brain change 





British birth cohort, 




Increased twitching and 
grimacing at age 15, 
speech defects, and 
cognitive impairment age 
8, 11, and 15 
 





1:5 on sex 






Paternal age ñ risk of BP for offspring of 
men 55 and older 
compared to men 20-24 
(OR = 1.37; CI: 1.02, 1.84) 
 





493 BP Sweden population 
based study, births 
1973-80, registry 
based 
Parental age Increased risk of BP for 
each 10 years increase in 
paternal age (HR = 1.28; 
CI: 1.11, 1.48); However, 
when controlling maternal 
age, finding is not 
significant. Maternal age 
was not associated with 
BP controlling for paternal 
age 
Controlling for spouses 











based study, registry 
based 




Brown et al 
(2013) 
94 BP, 746 
controls 
US Population 
based birth cohort, 
nested case-control 
Parental age Paternal age is not 
associated with BP 
(OR=1.03; CI: 0.98, 1.08) 
adjusted for maternal age.  
Maternal age is not 
associated with BP (OR = 
0.96; CI: 0.90, 1.02) 









British births during 
March 3-9, 1958, 
registry based 
Parental age Increased risk of Affective 
disorder for mothers older 
than 35 
OR: 2.29 (CI 1.19, 4.39) 
 
 
finding that maternal influenza during the first half of pregnancy increased the risk of SZ by a factor of 
three (Brown, Begg et al. 2004).  
 Additionally, maternal smoking during pregnancy (Talati, Bao et al. 2013); delayed motor 
milestones (van Os, Jones et al. 1997); being born preterm or small for gestational age, with a likely 
dose-response effect such that early birth is associated with higher risk (Done, Johnstone et al. 1991, 
Laursen, Munk-Olsen et al. 2007, Nosarti, Reichenberg et al. 2012, D'Onofrio, Class et al. 2013); season 
of birth (Torrey, Miller et al. 1997, Tsuchiya, Byrne et al. 2003, Disanto, Morahan et al. 2012); in utero 
exposure to severe famine (Brown, Susser et al. 1995, Brown, van Os et al. 2000); in utero exposure to 
acute war-related maternal stress (Kleinhaus, Harlap et al. 2013); and the death of a parent between 
gestation and age 17, although possibly only when the death is by suicide (Agid, Shapira et al. 1999, 
Mortensen, Pedersen et al. 2003, Tsuchiya, Agerbo et al. 2005, Khashan, McNamee et al. 2011, Appel, 
Johansen et al. 2013, Clarke, Tanskanen et al. 2013); are each associated with a significantly increased 
risk of BP.  
 However, being small for gestational age or having lower birth weight at birth are not reported to 
be associated with increased risk of BP (Ogendahl, Agerbo et al. 2006, Laursen, Munk-Olsen et al. 2007). 
Regarding maternal viral exposures, Mortensen et al analyzed neonatal dried blood spots in a population 
based study of 127 adults diagnosed with BP and controls matched on date of birth and sex to assess 
   
26 
 
whether viral infection increased the risk of later BP. For herpes simplex, cytomegalovirus, and T. gondii, 
each of which have previously been associated with SZ, they found no association with later BP 
(Mortensen, Pedersen et al. 2011). Similarly, hypoxia-ischemia appears not to increase the risk for BP, 
although it does for SZ, but this negative finding may reflect the small sample size which included only 10 
cases of BP (Zornberg, Buka et al. 2000), and another study found structural brain changes in adults with 
BP who had been exposed to prenatal and perinatal hypoxia (Haukvik, McNeil et al. 2013). A related 
issue is noted in a review of minor physical anomalies and risk for BP, in which the most commonly used 
measure of physical anomalies is said to poorly capture those conditions which are related to BP, 
resulting in a finding of no association (Tenyi, Trixler et al. 2009); but using a modified assessment, which 
re-categorized the shape of ear lobes and differentiated types of tongue furrow compared to the 
traditional scale, physical anomalies had a significant association with later BP (Akabaliev, Sivkov et al. 
2011, Sivkov, Akabaliev et al. 2013). However, no population based, prospective studies have reported 
on minor physical anomalies and BP. 
 Evidence on parental age and BP is mixed, with some population based studies finding an 
increased risk (Frans, Sandin et al. 2008, Menezes, Lewis et al. 2010), but others finding no association 
(Buizer-Voskamp, Laan et al. 2011, Brown, Bao et al. 2013). The nested case-control study of BP in the 
CHDS birth cohort found no increased risk for BP associated with paternal age, controlling for maternal 
age (Brown, Bao et al. 2013). Treating paternal age as a continuous variable, no association was 
observed with BP (OR=1.00, 95% CI=0.97-1.04, p=0.83), and this did not meaningfully change when 
controlling for maternal age (OR=1.03, 95% CI=0.98-1.08, p=0.29). A prior study found maternal age 
associated with an increased risk of BP, although it became attenuated when controlling for paternal age 
(Menezes, Lewis et al. 2010). This was also tested in the nested case-control drawn from the CHDS. 
Again, no association was observed between maternal age and BP (OR=0.98, 95% CI=0.95-1.02, 
p=0.31), and controlling for paternal age did not alter this result (OR=0.96, 95% CI=0.90-1.02, p=0.16). 
 In summary, it does appear from the available research that a number of specific prenatal and 
perinatal exposures are associated with an increased risk of BP. It also appears that a number of 
exposures which have been associated with SZ are not also associated with BP. However, many of the 
putative risks have been tested with small samples and are underpowered to find significant association 
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with BP. Thus, for many prenatal and perinatal risks, insufficient evidence exists to determine whether or 
not specific prenatal and perinatal exposures increase the risk of BP (Tsuchiya, Byrne et al. 2003, Scott, 
McNeill et al. 2006, Sanches, Keshavan et al. 2008). In addition to small sample sizes, inferences are 
made more difficult by inclusion criteria for birth and pregnancy complications that differ from study to 
study. Finally, the varying diagnostic criteria which often aggregates a number of types of affective 
disorders and diagnoses as outcomes makes determining what condition is being caused by obstetric 
complication or physical anomaly more difficult to parse (Sanches, Keshavan et al. 2008).  
 Despite these problems and the need for further research, it does appear that some prenatal and 
perinatal exposures significantly increase the risk for later onset BP. These findings lend support to the 
neurodevelopmental hypothesis of BP. 
 
Is there a BP prodrome? 
 Second, as in SZ, premorbid and prodromal symptoms have been identified in those who later 
developed BP. Evidence of identifiable, and preferably specific, symptom clusters during the premorbid 
and prodromal phases of BP would lend support to the neurodevelopmental hypothesis. In a prospective, 
population based study, Cannon et al reported a number of premorbid symptoms in people who later had 
a manic episode (Cannon, Caspi et al. 2002). This included social isolation, peer rejection, internalizing, 
and externalizing problems between the ages of 5 and 11, but no deficits in motor development or 
cognitive performance between the ages of 3 and 11. Some of these findings were not statistically 
significant, possibly due to the small sample size (n = 20), and a later study of this cohort reported only 8 
subjects met criteria for BP (Koenen, Moffitt et al. 2009). This problem of small sample sizes is common 
in studies of premorbid and prodromal BP, especially population based or prospective studies (Sanches, 
Keshavan et al. 2008, Howes, Lim et al. 2011).  
 In a large prospective cohort study of patients recruited into a mood disorder study, and followed 
for an average of more than 17 years, approximately twenty percent of subjects originally enrolled 
converted from depression to BP. Those who converted to BP had a younger age of onset of mood 
symptoms, had a higher number of subthreshold hypomanic symptoms, and a family history of BP 
(Fiedorowicz, Endicott et al. 2011). This is similar to Akiskal et al's study patients with major depression,  
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Akiskal et al 
(1995) 
22 BP 1; 








MDD to BP 
Those who converted had 
significantly more episodes and 
more severe index episodes; 
worse GAF scores; and worse 
physician rated anxiety, 
concentration, and social 
withdrawal, as well as more 
delusional and hallucinations 
Patients with 
depression who 
converted to BP over 
five years functioned 
worse and had greater 
numbers of symptoms 
Cannon et al 
(2002) 
20 BP Prospective 








Early childhood (through age 11) 
significantly impaired in social 
isolation, peer rejection, some 
language impairment 
Early childhood marked 
by social rejection and 
isolation 
Koenen et al 
(2009) 
8 BP Prospective 
birth cohort, 32 
year old follow-
up 
Childhood IQ Significantly increased IQ at age 
11 (OR = 3.1: CI: 1.18, 8.19)  
All 8 subjects had 
average or higher IQ 
scores at age 11 















BP had frequent mood ups and 
downs (OR = 14.33; CI: 4.94, 
41.59); family history of mania 
(OR = 6.81; CI: 1.95, 23.82); 
emotional lability or vegetative 
state (OR = 3.34; CI: 1.67, 6.66) 
Mood lability and family 
history are significant 
prodromal factors; 
social characteristics 
had no predictive value 
Meyer et al 
(2004) 
9 BP Prospective 
community 
study with 23 
years of follow-
up; participants 












GAF score lower in BP 
compared to no diagnosis group; 
IQ at ages 8-15 lower for BP; 
attentional, behavioral, and 
depressive symptoms more 
common for BP; impaired 
executive functioning 
More symptoms during 
prodrome and worse 
cognitive performance 
and functioning 















Risks at baseline 
which predict 
illness later in life 
Although hypomanic, manic, and 
depression symptoms were 
common in the prodrome, 
conversion to BP was very low 
Study is underpowered 
to predict BP 










time; number of 
symptoms  
Increased persistence and 
number of symptoms was 
associated with BP 
Many youth have some 
hypomanic symptoms 
which do not persist 
Fiedorowicz 
et al (2011) 










conversion to BP 
Hypomanic symptoms are 
associated with conversion to 
BP; family history of mania or 
hypomania increased risk; 
endorsing more symptoms at 
baseline increased risk (HR = 
1.24; CI: 1.09, 1.41); psychosis 
at intake predicted conversion 
and time to conversion 
Large observational 
study of patients with 
depression and risk of 
conversion to BP 
Thompson et 
al (2003) 
3 BP Prospective 
case study of 
high risk for 
psychosis clinic 




Depression symptoms at 
presentation; anxiety, racing 
thoughts, and mood swings 
Prospective observation 
of prodromal symptoms 







study, 2 year 
Prodromal 
personality 
Hypomania high risk group 









McCabe et al 
(2010) 






school grades at 
age 16 
Low and high grades associated 
with BP; 2 standard deviation 
units below mean: HR = 1.96 
(CI: 1.07, 3.56); 2 standard 
deviation units above mean: HR 
= 3.34 (CI: 1.82, 6.11) 
U shaped increased 
risk based on school 
grades at age 16 
Vonk et al 
(2012) 
53 BP twin 
pairs; 42 
healthy 
twin pairs  
Dutch registry 
identification of 






repeating a grade; 
special education; 
moved down to 
lower level of 
education 
Affected twins completed fewer 
years of school and 
underperformed during schooling 




which found that those who converted to BP had significantly more episodes and more severe index 
episodes; worse GAF scores; and worse physician rated anxiety, concentration, and social withdrawal, as 
well as more delusional and hallucinations (Akiskal, Maser et al. 1995). 
 A number of prospective, population based studies have explored what symptoms and 
characteristics might define the premorbid and prodromal periods of BP (Table 5). In summary, these 
studies find symptoms and behavioral markers, but few that are specific (Blechert and Meyer 2005, 
Beesdo, Hoefler et al. 2009, Olvet, Stearns et al. 2010, Tijssen, van Os et al. 2010, Schultze-Lutter, 
Schimmelmann et al. 2012, Ratheesh, Lin et al. 2013). The evidence that a prodrome exists is fairly 
strong, but whether it can be recognized prospectively remains in doubt. This is more true when the 
question is whether symptoms exist prior to onset, less so when the question is specificity and prediction 
of later onset BP. Hypomania, depression, mood lability, social isolation and withdrawal, and increased 
persistence of these symptoms have been found to define the premorbid and prodromal periods of later 
BP. Although non-specific, these symptoms and impairments denote the premorbid and prodromal 
periods, supporting the neurodevelopmental hypothesis.  
 This conclusion is consistent with other recent reviews which rely more on patient and 
retrospective studies (Conus, Ward et al. 2008, Skjelstad, Malt et al. 2010, Howes, Lim et al. 2011). 
Howes et al conclude that the fluctuating, cyclic nature of BP makes the identification of specific symptom 
clusters which might mark the prodrome, difficult. However, they suggest three stages of the prodrome 
based on their review: a cyclothymic, manic or hypomanic phase; followed by a worsening of symptoms 
phase possibly triggered by life events; and finally, a first manic episode (Howes, Lim et al. 2011). Two 
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studies are noted to have provided data to calculate specificity of symptoms in the prodromal phase, with 
many symptoms having high specificity, yet one of those two was a small sample of pediatric BP subjects 
with parental report of symptoms (Rucklidge 2008), the other reported only mood lability in a longitudinally 
followed community sample, with a specificity of 89 percent (Angst, Gamma et al. 2003). Skjelstad et al 
reviewed eight retrospective studies and concluded the prodromal period is marked by: irritability and 
aggressiveness, altered sleep patterns, mania, depression, anxiety, mood swings, and hyperactivity. 
However, all of the studies included in the review relied on patients or their parents to recall the onset of 
symptoms (Skjelstad, Malt et al. 2010). Conus et al reached similar conclusions, observing that in the 
months prior to the first manic episode, mood fluctuation, increased energy, sleep disturbance, irritability, 
and functional impairment may be apparent (Conus, Ward et al. 2008).   
 Evidence from patient studies provide some additional evidence. In a recent review of studies of 
children born to parents with BP, subjects thought to be at high risk to develop BP, reported disturbances 
in reality testing or thought disturbance among those offspring as a potential marker of prodrome 
(Narayan, Allen et al. 2013). However, only a few of the studies were longitudinal, and even those have 
not yet followed subjects through the primary window of risk for developing BP. Similar to the lack of 
specificity observed in the population studies, disturbance in reality testing is not specific to BP. The 
authors proposed further research on the developmental course of thought disturbances across a BP-SZ 
spectrum, rather thought disturbance being diagnostically specific.  
  A number of researchers have attempted to develop assessment instruments to improve the 
prediction of BP during prodrome. The symptoms identified for inclusion in these instruments have 
included: sleep and mood alterations, anxiety, fearfulness, and dissociative symptoms (Leopold, Ritter et 
al. 2012). Based on a literature review, Bechdolf et al created a "Bipolar At Risk" algorithm which includes 
a combination of mood fluctuations, symptom constellations related to mania or related to depression, 
and genetic risk (Bechdolf, Nelson et al. 2010, Bechdolf, Ratheesh et al. 2012). Specificity of the at risk 
criteria was reported to be 90 percent and sensitivity 83 percent. A third research group's review, seeking 
an approach to predicting BP, concluded that three key features could aid prediction: genetic high risk, 
environmental high risk (such as childhood abuse), and high risk biomarkers (Brietzke, Mansur et al. 
2012). Of note, following a brief review of symptom clusters identified by others as marking the prodrome 
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of BP, Brietzke et al conclude that a lack of longitudinal and prospective data, and the non-specificity of 
identified symptoms, make utilization of the phenomenological features unlikely. 
 In summary, it appears that a prodrome in BP does occur, marked by broad symptom clusters. 
Yet, the symptoms are difficult to identify prospectively and have little specificity. This is similar to the 
problems in identifying people who will develop SZ as well, where high risk studies find conversion rates 
of about twenty-five percent of those identified (Simon, Velthorst et al. 2011). Certainly, further research 
may better identify specific symptom manifestations that denote the BP prodrome, but at this time, it is 
difficult to differentiate the BP prodrome from any number of other conditions and symptom clusters. 
Nevertheless, even though not specific, the research does clearly support the presence of premorbid and 
prodromal symptoms which in turn supports the neurodevelopmental hypothesis. 
 
High risk and first episode 
 Third, high risk and first episode psychosis subjects manifest a number of identifiable 
symptomatic differences compared with both healthy controls and people with other psychiatric disorders. 
As noted in a recent review, because nearly all the high risk studies are conducted with those who seek 
help or have insight into some symptoms, this research is necessarily not representative of the population 
at risk for, or those who develop, BP; and because the conversion rates are low, some of the identified 
symptoms that qualify people as high risk, are not specific (Fusar-Poli, Yung et al. 2014). Regardless, 
some information about the course of those people with symptom clusters that may be predecessors to 
BP is observed in these studies which focus on the period prior to and including the onset. The existence 
and observation of symptoms which bring people into treatment and lead to diagnosis are a piece of 
evidence indicating that the illness course begins prior to first episode psychosis; and symptoms used to 
identify those people deemed to be at high risk may reflect neurodevelopmental processes more directly 
(Wood, Pantelis et al. 2008, Fusar-Poli, Deste et al. 2012). For instance, in a population based study of 
first episode psychosis, those with BP performed better, in general, than those with other psychotic 
disorders, but still performed worse than population controls, despite low power because the study 
included only 37 people with mania or BP (Zanelli, Reichenberg et al. 2010). Similarly, as noted above, 
high risk studies have identified some clinical and behavioral symptoms which appear to mark the BP 
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prodrome and first onset, including mood lability, family history of psychosis, racing thoughts, anxiety, and 
irritability (Skjelstad, Malt et al. 2010, Howes and Falkenberg 2011).  





Study type Specific high risk 















Cognition at first 
episode 
BP had statistically significantly 
lower current IQ (approximately 
6 points lower); semantic verbal 
fluency was significantly 
impaired (OR = 5.49; CI: 1.87, 
9.11 compared to all controls) 
Specific deficit in verbal 
fluency 
Zanelli et al 
(2010) 




Cognition at first 
episode 
BP have equivalent current IQ as 
controls; significantly impaired 
delayed verbal memory and 
category fluency compared to 
controls, non-significantly 
impaired on processing speed 
and executive functioning 
BP have impaired 
performance but out-





73 BP Population 
based, 13 year 
prospective first 
episode 
Symptom severity BP had lower premorbid 
adjustment scores and 
performed better on an executive 
functioning interview compared 
to those with major depression 
with psychotic features 
Comparison to other 
people at first episode 
Bechdolf et 
al (2010) 







BP at risk criteria 
development 
Those who converted to BP had 
depressive symptoms prior to 
onset, and either cyclothymic 




symptom scale for 
prediction of BP 
Olvet et al 
(2010) 






Compared to non-converters, BP 
had 10 point lower IQ score and 
lower global cognition score 
(non-significant); significantly 
more severe positive symptoms 
Prodromal BP lower 
scores on cognitive 
testing and more 
positive symptoms 
Schultz-
Lutter et al 
(2012) 
10 BP Clinical high 









BP group less symptomatic than 
the SZ group; Psychotic features 
of Affective disorder and SZ are 




Affective disorder with 
psychotic features and 
without, and SZ 
Ratheesh et 
al (2013) 





High risk clinic 
group; mean 





GAF at baseline significantly 
lower for BP; BP performed 
significantly worse than controls 
on IQ, abstract visual reasoning,  
processing speed and attention 
No differences between 
BP and non-converters 
 
 Prospective studies of those at high risk for BP report a number of symptoms and deficits which 
are associated with onset (Table 6). It remains difficult to distinguish between those who will develop BP 
and those who will develop SZ or major depression as a result of symptom non-specificity (Olvet, Stearns 
et al. 2010, Scott, Hermens et al. 2013). One recent first episode psychosis study, however, differentiates 
major depressive disorder with psychosis onset from that of SZ and BP, finding that first episode major 
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depression was evenly distributed across life-span, whereas first episode BP and SZ are primarily 
disorders of late adolescence and young adulthood (Owoeye, Kingston et al. 2013).  
 In summary, studies of those considered to be at high risk for BP have not identified specific 
symptoms that predict BP. Because of the low conversion rates in most of these high risk studies, the 
evidence of what constitutes high risk for BP is not condition specific. Moreover, even studies aimed at 
specificity, such as the clinical high risk study for SZ by Olvet et al in which eight subjects unexpectedly 
converted to BP, the outcome diagnosis is very difficult to predict (Olvet, Stearns et al. 2010). In 
summary, the high risk for BP studies offer limited support for the neurodevelopmental hypothesis 
because the small numbers who have been enrolled and go on to develop BP, and because of the lack of 
specificity of symptoms. In this way, however, the at-risk for BP research overlaps with the at-risk for SZ 
research in that both conditions exhibit similar symptom patterns and risk patterns, and neither set of 
those patterns predict disease onset well. 
 
Neurocognition 
 A final critical pillar of support for the neurodevelopmental hypothesis of SZ is the evidence of 
cognitive impairment during the premorbid and prodromal periods (Keshavan, Kennedy et al. 2004, 
Reichenberg and Harvey 2007, Woodberry, Giuliano et al. 2008, Mesholam-Gately, Giuliano et al. 2009, 
Consortium 2013, Olvet, Burdick et al. 2013). For instance, a nested case-control study of SZ drawn from 
the same CHDS birth cohort as in the present research, compared childhood cognitive performance as 
measured by the Peabody Picture Vocabulary Test (PPVT) given at ages 5 and 9-11, and re-
administered in adulthood, to examine the course of cognitive functioning over 33 years. This study found 
a ten point difference in the early childhood PPVT, with those who would later develop SZ performing 
more poorly than the matched controls. In adulthood, the gap in performance was wider, with those who 
had developed SZ scoring 15 points below the controls (Kremen, Vinogradov et al. 2010). The ten point 
difference observed in childhood scores is consistent with the neurodevelopmental hypothesis of SZ. 
 Evidence of cognitive impairment at each of the illness stages of BP also tend to support the 
neurodevelopmental hypothesis, but the effect sizes of impairment tend not to be as large as those 
observed with SZ, and the impairments tend to be domain specific as opposed to the broad, global 
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deficits seen with SZ. On average, people who are later diagnosed with BP are observed to have 
cognitive impairment during all phases of illness, including during the premorbid period of development 
(Reichenberg, Weiser et al. 2002, Martinez-Aran, Vieta et al. 2004, Daban, Martinez-Aran et al. 2006, 
Goodwin, Martinez-Aran et al. 2008, Kurtz and Gerraty 2009, Reichenberg, Harvey et al. 2009, Bearden, 
Woogen et al. 2010, Harvey, Wingo et al. 2010, Pol, van Baal et al. 2012, Hill, Reilly et al. 2013).  
 A number of meta-analyses and reviews have reported domain specific significant cognitive 
impairment in people with BP (Bearden, Hoffman et al. 2001, Quraishi and Frangou 2002, Savitz, Solms 
et al. 2005, Daban, Martinez-Aran et al. 2006, Goodwin, Martinez-Aran et al. 2008, Stefanopoulou, 
Manoharan et al. 2009, Bearden, Woogen et al. 2010, Harvey, Wingo et al. 2010, Lim, Baldessarini et al. 
2013). Meta-analyses of euthymic patients with BP have also found cognitive deficits in a number of 
domains, reporting moderate to large effect sizes even after controlling for a number of potential 
confounders (Robinson, Thompson et al. 2006, Torres, Boudreau et al. 2007, Arts, Jabben et al. 2008, 
Bora, Yucel et al. 2009, Kurtz and Gerraty 2009, Latalova, Prasko et al. 2011, Mann-Wrobel, Carreno et 
al. 2011, Bourne, Aydemir et al. 2013). The cognitive domains in which deficits are observed are 
executive functioning, verbal learning, verbal memory, sustained attention, and psychomotor speed. The 
effect sizes are moderate and large in these domains. These studies are often used to support the notion 
that cognitive impairment is a trait of those who develop or have BP. Similarly, few differences are 
observed when comparing cognitive deficits between BP 1 and BP 2, with some slightly better 
performance on verbal memory for those with BP 2, but generally similar domains of impairment (Bora, 
Yucel et al. 2011, Sole, Martinez-Aran et al. 2011, Sole, Bonnin et al. 2012); small differences are 
observed when comparing BP with psychosis and without on specific domains (Bora, Yucel et al. 2010); 
and impairment is observed across all phases of illness, with executive function performance decline 
during mania (Martinez-Aran, Vieta et al. 2004, Ryan, Vederman et al. 2012). The evidence of cognitive 
impairment across mood phases and in remitted states supports the hypothesis that cognitive deficits are 
components of the illness (a trait) rather than reflecting a disease state which varies according to mood. 
These findings also suggest that investigating at what stage of illness (premorbid, prodromal, at first 
onset) cognitive impairment becomes observable. 
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 Population based studies of premorbid functioning have found differences between those who 
develop BP and the general population (see Table 7). A review of population based studies concluded 
that the evidence of premorbid cognitive impairment does not yet support a conclusion that such 
impairments define a trait of later BP (Kravariti, Kane et al. 2009). Although draft board 
neuropsychological batteries lack the specificity and breadth of a complete functional assessment, they 
do provide useful population based information on a testing battery that mimics IQ assessments. One 
large Danish draft board study reported small IQ difference for both BP and unipolar depression 
compared with the general population but no significant differences between illnesses (Sorensen, Saebye 
et al. 2012), and a second Danish draft board study observed small deficits in IQ for people who 
developed affective disorders (as well as schizophrenia; non-schizophrenic, non-affective psychotic 
disorder; neurotic or stress disorder; and personality disorders) compared to population controls (Urfer-
Parnas, Mortensen et al. 2010). A third Danish draft board study of all men born in 1953, compared 
testing at ages 12 and 18 for those who later developed BP, also reporting impaired cognition compared 
to those without BP, but the sample size (N=16) is reported to be too small to offer stable results (Osler, 
Lawlor et al. 2007). A more recent analysis of four Swedish birth cohorts which compared trend data for 
testing at ages 13 and military induction testing at age 18 reported that the 18 subjects with BP performed 
better than the population at both time points on verbal, spatial, and inductive reasoning (MacCabe, 
Wicks et al. 2013). However, a Finnish population based cohort study, analyzing conscript testing at ages 
18-19, reported that worse premorbid performance on a test of visuospatial ability predicted later onset 
BP (Tiihonen, Haukka et al. 2005). 
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Study type Specific cognitive 
domains 
Results Significance 
Cannon et al 
(2002) 





Only motor development was 
significantly impaired; language 
was impaired or above average 
at different ages 
Receptive language is 
low at ages 3 and 9, 
high at 5 and 7, study is 
underpowered 
Reichenberg 













No association between 
premorbid tests and BP 
No impairment observed 
Zammit et al 
(2004) 











No association between 
premorbid IQ and later BP 
IQ is coded on a 9 point 
scale 
Meyer et al 
(2004) 
9 BP Prospective 
community 
study with 23 
years of follow-
up; participants 












IQ at ages 8-15 lower for BP; 
attentional, behavioral, and 
depressive symptoms more 


















No association between 
premorbid IQ and later BP 
Analyses focused on 
SZ, limited detail on BP 
Tiihonen et 
al (2005) 








Premorbid impairment on 
visuospatial reasoning  
performance and higher than 




Osler et al 
(2007) 






at ages 12 and 
18, visuospatial, 
arithmetic, verbal 
Impairment observed at both 12 
and 18 in all areas, but non-
significant 
Impairment prior to 
onset is similar to those 
who develop SZ, but the 
study is underpowered 
for BP 
Koenen et al 
(2009) 
8 BP Prospective 
birth cohort, 32 
year old follow-
up 
Childhood IQ Significantly increased IQ at age 
11 (OR = 3.1: CI: 1.18, 8.19)  
All 8 subjects had 
average or higher IQ 
scores at age 11 
MacCabe et 
al (2010) 






from ages 15-6 
Both high and low grades had 
higher risk for BP: 2 or more 
standard deviations above 
mean had a 3.34 increased risk 
(adjusted) and 2 or more below 
had a 1.96 increased risk 
(adjusted) 
U shaped increased risk 
for BP 
Urfer-Parnas 















Compared to controls, 
significantly lower IQ scores 
All psychiatric groups 
performed worse than 
controls, those with 
affective disorder 















Although IQ was lower 
compared to controls, it was 
less than 2 points lower; mean 
educational level was equal to 
controls 
No significant premorbid 
IQ difference observed 
Vonk et al 53 BP twin Dutch registry School Affected twins completed fewer Underperformed at 
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(2012) pairs; 42 
healthy 
twin pairs  
identification of 





repeating a grade; 
special education; 
moved down to 
lower level of 
education 
years of school and 
underperformed during 
schooling 









at ages 13 and 
18, verbal, spatial, 
inductive 
Performance is better than 
controls on all measures at both 
ages periods 
Although verbal and 
spatial decline between 
13 and 18, BP perform 
better than control on all 
tests at both times 
Ratheesh et 
al (2013) 





High risk clinic 
group; mean 




BP performed significantly 
worse than controls on IQ, 
abstract visual reasoning,  
processing speed and attention 
No differences between 
BP and non-converters 
 
 Olvet et al recently reviewed longitudinal, family, and first episode neuropsychological studies to 
assess whether cognitive impairment could serve as a predictor of later onset BP (Olvet, Burdick et al. 
2013). They concluded that some domain specific functions (executive and memory) might serve as 
predictors, and have been shown to be consistently impaired in those who later develop BP. 
 In a prospective study which followed children into adulthood, children tested between ages 3 and 
11 who later developed bipolar mania, had receptive and expressive language skills that varied between 
testing periods compared with controls (expressive language was higher at age 3, lower at ages 5 and 7, 
and higher at age 11; receptive language was lower at age 3, higher at 5 and 7, and lower at age 11; IQ 
was slightly higher at age 7 and lower at age 11), and more behavioral difficulties (Cannon, Caspi et al. 
2002). This study included only 20 people who developed mania in adulthood through age 26, and none 
of the scoring differences reached statistical significance. Another prospective study, this one of children 
at high risk for BP followed for 23 years, reported that the 9 people who developed BP had lower IQ 
scores than those who developed unipolar (n = 22) and those without mood disorder (n = 64), although all 
the scores are within the normal range (Meyer, Carlson et al. 2004).  In addition, they found that those 
who developed BP performed significantly worse on executive functioning measures prior to onset. 
 An exploratory high risk for psychosis study prospectively followed and compared 16 people who 
converted to BP to 46 who did not convert to psychosis matched on age and sex, and 66 healthy 
comparison subjects (Ratheesh, Lin et al. 2013). At baseline, the clinical characteristics of all those at 
high risk were similar; subjects who later developed BP had lower full scale IQ scores compared to 
controls (approximately twelve points lower than healthy controls and four points lower then other high 
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risk subjects), and performed significantly worse on a measure of executive functioning. Another 
comparison of high risk subjects, this one comparing pre-conversion functioning for 8 subjects who later 
converted to BP, 24 who later converted to SZ, and 115 non-converters, found that at baseline the BP 
subjects had IQ scores approximately 10 points lower than non-converters, although this was non-
significant likely due to low power (Olvet, Stearns et al. 2010). Although reporting that the BP group 
performed worse than non-converters on other neuropsychological tests, and that they also demonstrated 
more variance in scoring, the authors note that the study was underpowered. 
 A twin study of school success observed that those who later developed BP had fewer years of 
education and worse performance compared with matched, control twins (Vonk, van der Schot et al. 
2012), and this finding is also reported in case-control studies (Glahn, Bearden et al. 2006). Cannon et al 
demonstrated worse premorbid sociability, adjustment, and schooling for those who later developed BP 
(Cannon, Jones et al. 1997). However, others have reported that both low and high premorbid school 
performance is a risk factor for BP based on a longitudinally followed, nationally representative cohort 
(MacCabe, Lambe et al. 2010). 
 In summary, cognitive functioning prior to the onset of illness, one key pillar of the 
neurodevelopmental hypothesis, remains to be more fully explored in BP. It appears from the available 
research, that domain specific impairments are documented at least during the prodromal period, but that 
during the premorbid period, it is less clear, with conflicting evidence. Further investigation of the mixed 
evidence of premorbid cognitive functioning in those who later develop BP may further our understanding 
of whether  BP should be considered a neurodevelopmental illness. 
 On average, people who are later diagnosed with BP are observed to have cognitive impairment 
during all phases of illness, including during the premorbid period of development (Martinez-Aran, Vieta et 
al. 2004, Goodwin, Martinez-Aran et al. 2008, Kurtz and Gerraty 2009, Bearden, Woogen et al. 2010, Hill, 
Reilly et al. 2013), but the impairments are in specific cognitive domains, unlike the broad impairment 
across many domains observed in SZ, and are typically not as severe as those seen in premorbid and 
prodromal SZ (Reichenberg, Weiser et al. 2002, Daban, Martinez-Aran et al. 2006, Reichenberg, Harvey 
et al. 2009, Harvey, Wingo et al. 2010).  
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 Neurocognitive deficits are consistently observed in premorbid and prodromal BP. Some large 
studies have also reported high IQ as a risk for BP (Table 7). This U shaped cognitive risk differs from 
what is observed in SZ, where impaired cognition is much more common. Those studies which report 
impairment in cognitive functioning in BP also identify specific domains of deficit, in contrast to SZ in 
which the deficits are reported to be more global. Sufficient evidence supports the presence of these 
cognitive deficits throughout the course of the various mood and remission states after onset of BP as 
well. The presence of cognitive impairment in specific domains and superior performance on global and 
school measures, provides support for the neurodevelopmental hypothesis BP.  
 
Discussion 
 The neurodevelopmental basis for BP is not clear cut, but the majority of accumulating studies, 
especially from population based research with sufficient power, supports that the illness is one 
characterized by an altered, pathological, or delayed maturation of the developing brain, that progresses 
through stages, shifting the neurodevelopmental trajectory prior to onset. Nevertheless, further research 
is needed to derive better specificity of the stages of pre-onset illness, the causes which precipitate 
changes, and the mechanisms by which they occur.   
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Paper 2: Prenatal and perinatal environmental risks for bipolar 
 The causes of Bipolar disorder (BP) are not currently known, and the early life risks for later onset 
illness have been examined in only a limited number of studies to date. Historically, BP has been thought 
to be related closely to SZ, and as the neurodevelopmental hypothesis of SZ has become increasingly 
accepted, a similar hypothesis has been applied to BP. The neurodevelopmental hypothesis posits that 
altered, pathological, or delayed maturation of the developing brain, long before the manifestation of 
disease, shifts the neurodevelopmental trajectory, followed by later life onset of psychiatric illness (Oneal 
and Robins 1958, Fish, Shapiro et al. 1965, Nasrallah and Weinberger 1986, Murray and Lewis 1987, 
Meyer and Feldon 2010, Millan 2013). The evidence supporting the neurodevelopmental hypothesis of 
BP is less robust than the evidence supporting the hypothesis of SZ, both because of less research 
attention and because the evidence that does exist has been less clear cut for BP, especially concerning 
prenatal and perinatal risks. 
 The neurodevelopmental approach to the origin and course of SZ and BP holds promise for 
better outcomes because it searches for the causes and mechanisms which result in illness later in life, 
opening the potential for earlier and more effective intervention and prevention. As suggested by Insel, 
the neurodevelopmental approach identifies stages of disease progression, each of which may offer 
specific types of intervention and prevention (Insel 2010). Another way to ask this question is: during 
which periods do the divergences from typical developmental course occur, and why have they occurred? 
The neurodevelopmental hypothesis suggests that the divergences may begin before conception and that 
the risk for them continues through illness onset, at least. For each symptom cluster that constitutes the 
diagnostic criteria for illness, the timing and mechanism of divergence offers the potential for prevention 
or remediation. In order to identify the interventions and preventive steps that might work, further research 
on the antecedent risks, mechanisms, and causes are needed. 
 In order to test some specific components of the neurodevelopmental hypothesis of BP and 
compare them to what is known about SZ, both prenatal and perinatal exposures should be considered. 
Here, one of each type of environmental exposure is investigated for possible associations with later 
onset BP: the prenatal infectious exposure to toxoplasmosis and the administration of oxytocin to induce 
labor. Examining these two risks will allow for determination of specificity of exposures and testing of 
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potential mechanisms.  A finding that prenatal exposures such as these are risks for later illness would 
support the idea that BP is a neurodevelopmental disease, and whether either exposure has an effect on 
cognition during the developmental period may elucidate the role of cognitive impairment in later illness. 
 
Prenatal exposure: Toxoplasma gondii 
 Toxoplasma gondii (T. gondii), a ubiquitous intracellular parasite (Scheld, Whitley et al. 2004, 
Remington 2011), is able to cross the placental barrier to cause congenital malformations (Sullivan and 
Jeffers 2012); it infects neurons, enabling its own spread throughout the central nervous system, causing 
negative neuropsychiatric outcomes, including psychiatric illnesses (Carruthers and Suzuki 2007, 
Fekadu, Shibre et al. 2010). A number of studies of adults have found elevated seroprevalence for T. 
gondii among those with SZ and BP (Torrey, Bartko et al. 2007, Tedla, Shibre et al. 2011, Arias, 
Sorlozano et al. 2012, Torrey, Bartko et al. 2012).  
 The association between serologically documented maternal T. gondii and offspring BP has not 
previously been assessed. However, research in the CHDS birth cohort found an association between 
serologically documented maternal T. gondii IgG antibody during pregnancy and an increased risk of 
offspring schizophrenia spectrum disorder (Brown, Schaefer et al. 2005). Analyzing maternal sera 
obtained during pregnancy and comparing moderate (1:16 to 1:64) and high (>1:128) IgG antibody titers 
to a negative referent group (<1:16), Brown et al found a 2.61 times increased risk for SZ among those 
with high titer compared with the referent. That finding has been replicated (Mortensen, Norgaard-
Pedersen et al. 2007, Blomstrom, Karlsson et al. 2012) and confirmed in a meta-analysis (Torrey, Bartko 
et al. 2012). Further, at least one prospective, population based study found T. gondii associated with risk 
of SZ when measured prior to onset of symptoms (Pedersen, Stevens et al. 2011). However, no 
association was observed between maternal T. gondii and offspring BP (Mortensen, Pedersen et al. 
2011), although that study analyzed dried blood spots on filter paper obtained from the infant and not 
maternal sera obtained during pregnancy. This difference could be important if placental transfer of IgG 
diluted the measurable effect or the aging and preservation of the blood spot on filter paper made 
detection more difficult. 
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 Additionally, in SZ an association has been observed between maternal T. gondii and offspring 
cognition. Only a limited number of studies have examined cognition in offspring of exposed mothers. 
Brown et al reported an association of maternal infections, including T. gondii, with impaired executive 
functioning in SZ (Brown, Vinogradov et al. 2009). For adult exposure to the virus, limited evidence 
suggests no association (Yolken, Torrey et al. 2011, Guenter, Bielinski et al. 2012), but exposure during 
neurodevelopment, when maternal inflammation and immuno-response affects fetal processes, remains 
to be tested more comprehensively.  
 This association of T. gondii with cognition is not fully developed, but both animal models and 
observational studies support an association (Kannan and Pletnikov 2012). One prior study found 
children exposed prenatally to T. gondii and treated had significant neurologic and cognitive impairment 
through childhood (Roizen, Swisher et al. 1995), and evidence indicates that T. gondii continues to 
spread and cause damage in the fetal brain once the maternal immune system responds to the infection 
(Ferguson, Bowker et al. 2013). A recent international meta-analysis found an association between T. 
gondii and learning difficulties, developmental delays, impaired cognition, and vision loss or deficit in 
children with congenital exposure (Mwaniki, Atieno et al. 2012).  
 Prenatal exposure to T. gondii’s possible association with impaired cognition, and its association 
with SZ, makes it an important antecedent to test as a possible neurodevelopmental risk for BP. Much of 
the prior evidence is either ecological or based on adult exposure rather than prenatal exposure which 
would affect development, making determinations about mechanism untestable. The mechanism by 
which the parasite proliferates, specifically affecting the central nervous system, suggests that prenatal 
exposure is likely an important period of risk for neuronal maldevelopment. Thus, the purported 
mechanism by which T. gondii could affect neurodevelopment, both impairing cognition and increasing 
risk for psychiatric illness, in which cognitive impairment may mediate the association between T. gondii 
and later psychosis, can be analyzed in this case-control study directly to assess the neurodevelopmental 
effects of exposure. 
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Perinatal exposure: Oxytocin to induce labor 
 The evidence that obstetric complications increase the risk for BP is mixed, with methodological 
concerns hampering the understanding of the associations or absence of associations. For instance, 
grouping obstetric complications into scales treats all the complications the same, without determining the 
risk associated with a specific complication (Lewis and Murray 1987, Verdoux and Bourgeois 1993, 
Kinney, Yurgelun-Todd et al. 1998, Buka and Fan 1999, Buka, Goldstein et al. 2004, Scott, McNeill et al. 
2006, Singh, DelBello et al. 2007). 
  This study used a single perinatal complication, induced labor by administration of oxytocin, 
identified prospectively and documented in medical charts contemporaneously, to assess one specific 
and common procedure. Inducing labor may be undertaken because of labor difficulties or for other 
reasons, but the procedure is relatively common and understudied. The rate of induction has increased in 
recent decades, with oxytocin now being the most used means for inducing (Mealing, Roberts et al. 2009, 
Moleti 2009). However, oxytocin to induce labor has been shown to have risks for the mother and 
neonate (Buchanan, Patterson et al. 2012). These risks include a greater need for neonatal intensive care 
and lower Apgar scores (Oscarsson, Amer-Wahlin et al. 2006, Selo-Ojeme, Rogers et al. 2011); an 
increased risk for ADHD (Kurth and Haussmann 2011); and an increased risk for autism (Gregory, 
Anthopolos et al. 2013).  
 Excess oxytocin, as measured in adults and in animal models, has been associated with 
impairments in learning, attention, and memory, and oxytocin is reported to reduce cognitive ability in 
experimental models (Demitrack and Gold 1988). During the peripartum period, neurons in the limbic 
regions of the brain have an increased density of oxytocin receptors, suggesting a developmental window 
of importance for the social and bonding behaviors associated with endogenous oxytocin (Zingg, Bourque 
et al. 1998). The hypothesized mechanism by which maternal oxytocin exposure may affect offspring 
proposes that oxytocin causes fetal hypoxia, restricts neural blood flow, and increases fetal bilirubin and 
the risk of jaundice (Drew and Kitchen 1976, Connor and Seaton 1982).  
 The finding that SZ is associated with obstetric complications has been frequently reported. Yet 
no research to date has examined the association with oxytocin in either SZ or BP, despite its relationship 
to other psychiatric illnesses and a mechanism of action which is hypothesized to increase the risk for SZ 
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in other obstetric complications. Similarly, although some obstetric complications have been associated 
with childhood cognitive deficits (Seidman, Buka et al. 2000, Leitner, Fattal-Valevski et al. 2007), no 
studies of oxytocin's potential association with cognitive performance have been conducted.  
 Maternal oxytocin to induce labor, therefore, merits further investigation for its association with BP 
and cognitive impairment, given the possible mechanisms by which it alters neurophysiology and its use 
during birth when the developing brain is at increased risk. The primary hypotheses tested here are: 1) 
whether the offspring of mothers who received oxytocin to induce labor are at greater risk for later life BP; 
2) whether the offspring of mothers who received oxytocin perform worse on childhood cognitive testing; 
and 3) if oxytocin is associated with both BP and cognition, whether cognitive performance mediates the 
association between oxytocin and BP. 
 Secondary analyses are also conducted to attempt to differentiate the possible effect of oxytocin 
as an agent and oxytocin as a proxy marker (confounding). Three sets of analyses were conducted: 1) 
examining prolonged labor: it is possible that prolonged labor is an antecedent of oxytocin, where 
oxytocin is given to induce if labor was extended, or that oxytocin and labor length share a common 
cause and labor length is associated with BP. Length of labor could be a confounder or an antecedent or 
not associated with BP, and each of these suggests different potential points of prevention or intervention; 
2) analgesics: it is possible that analgesics given during labor have a direct effect on BP and share a 
common cause with oxytocin, or that they interact with oxytocin to increase the risk of BP. This analysis 
addresses whether any drug intervention increases the risk of BP, or if the possible effect is specific to 
one medication, and also tests an interaction effect which has been hypothesized (Oscarsson, Amer-
Wahlin et al. 2006); and 3) delivery type: it is possible that delivery type, dichotomized between cesarean 
and vaginal, is associated with BP and shares a common cause with oxytocin to induce labor. For 
instance, a common condition during labor may have led doctors to recommend cesarean rather than 
oxytocin, and it is the common cause of both delivery type and oxytocin which explains a possible 
relationship with BP. If an unmeasured confounder causes both oxytocin use and any of the three 
testable covariates, both oxytocin and that covariate would be associated with BP. If, on the other hand, 
oxytocin is associated with BP, but one or more of the other covariates is not, then the association 
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 The Child Health and Development Study (CHDS) is a large, representative birth cohort, 
containing 19,044 live births. This cohort has been followed prospectively, with prenatal serologic 
samples obtained during pregnancies, perinatal measures obtained during routine medical care, 
childhood cognitive assessment performed at ages 5, 9-11, and 15-17 on subsets of the birth cohort, and 
psychiatric diagnoses confirmed in adulthood. Using a nested case-control design to obtain all BP cases 
and matched controls from the CHDS, this research investigates the relationship between serologically 
obtained prenatal exposure (T. gondii) and BP, and a perinatal exposure (oxytocin) and BP, as well as 
testing whether these effects are mediated by cognition.  
 Cases and controls for the Prenatal Factors and Bipolar Disorder Study were drawn from the 
CHDS birth cohort (van den Berg, Christianson et al. 1988). The CHDS recruited nearly all pregnant 
women receiving obstetric care from the Kaiser Permanente Medical Care Plan, Northern California 
Region (Kaiser) in Alameda County, California between 1959 and 1966. Contemporaneously completed 
medical records, maternal interviews, child assessments, and other sources were generated 
prospectively during the course of prenatal and perinatal medical care provided by Kaiser. Kaiser reflects 
the population of the Bay Area of California at the time, providing care to approximately 30% of the 
population of Alameda county, with some underrepresentation at both the extremes of income. This birth 
cohort has been extensively studied for prenatal and other early developmental risk factors for SZ 
(Susser, Schaefer et al. 2000). 
 
Case Identification 
 People with potential DSM-IV BP, which included BP I, BP II, BP NOS, and BP with psychotic 
features, were ascertained by screening procedures which used data from three sources: Kaiser’s 
electronic medical records database, the Alameda County Behavioral Health Care Services (ABHCS) 
database, and a mailing to the entire living CHDS birth cohort (mothers and children). This approach 
   
46 
 
sought to maximize ascertainment of individuals with BP. CHDS cohort members who belonged to Kaiser 
when first treated would have been ascertained from this source. Subjects who left Kaiser prior to the first 
treatment of BP and who did not have other health insurance, but who still lived in Alameda County, 
would likely have been treated by ABHCS and therefore ascertained. Subjects who were not ascertained 
by these two approaches were ascertained by a mailed survey to the entire cohort. 
 The ascertainment process identified 448 subjects who potentially met the criteria for BP and 
psychotic disorder. 
 
Ascertainment of Kaiser subjects 
 Subjects with potential BP (and other psychotic disorders) were identified by screening Kaiser's 
inpatient and outpatient databases. Computerized record linkages between CHDS and Kaiser identifiers 
were conducted on these databases. The inpatient database included all psychiatric hospitalizations of 
Kaiser members regardless of the hospital at which treatment is received. This covered the period from 
1981-2010. Those with discharge diagnoses of ICD-9 295-298 from the Kaiser inpatient database were 
considered as potential BP subjects. A database of outpatient treatment was introduced in 1981, but did 
not contain searchable codes for diagnoses until 1995. Potential BP cases from the outpatient database 
were considered to screen positive if they received ICD-9 diagnoses of 295-298 excluding unipolar major 
depressive disorder. Case ascertainment also used the Kaiser outpatient pharmacy database, which 
commenced in 1992. Cases screened positive based on prescriptions for mood stabilizing medications 
used in the treatment of BP (lithium, carbamazepine, valproic acid). Before contacting subjects who were 
currently enrolled in Kaiser, the subject’s treating psychiatrist was contacted, informed about the study, 
and asked to approve contact with the subject to seek his/her consent to participate. 
 Any subjects identified by these methods were invited to participate in the study, receiving a letter 
to the most recent address, and those who did not refuse contact by returning a postcard, were contacted 
to arrange an appointment for a diagnostic interview. Up to several repeat appointments were scheduled 
for subjects who failed to attend the interview. Extensive efforts were made to locate individuals who were 
no longer living at the most recent listed address, including Department of Motor Vehicles records, 
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telephone directories, and contacting the subjects’ parents or siblings from CHDS or Kaiser files. Mortality 
records, reverse directories, jail searches, and visits to previous addresses were also used as necessary.  
 
Ascertainment by Alameda County Behavioral Health Care Services (ABHCS)  
 Outpatients with potential BP were also ascertained by electronic record linkage between the 
CHDS and ABHCS identifiers. The ABHCS database included treatment from 1993-2009. These subjects 
screened positive based on ICD-9 outpatient diagnoses of 295-298, excluding unipolar major depressive 
disorder. Procedures for finding and recruiting these potential subjects were similar to those described 
above for ascertainment by Kaiser. 
 
Ascertainment of CHDS birth cohort by mailed questionnaire and follow-up 
 The third method of ascertainment was initiated by letters mailed to all living mothers (N=6,971) 
and cohort members (N=13,009) with known addresses in the entire CHDS cohort (excluding families in 
which potential cases had already been identified in the Kaiser and/or ABHCS) along with a questionnaire 
on mental and physical health. This was conducted from 2009-11. Questionnaire respondents who 
reported “mental health problems” in an eligible cohort member (including the respondent him or herself) 
were contacted by a trained Kaiser study interviewer who administered the Family Interview for Genetic 
Studies (FIGS) to screen for possible BP or psychotic illness in the cohort member. If the FIGS indicated 
at least one bipolar and/or psychotic symptom (delusions/hallucinations), then the cohort member was 
considered to have screened positive, and was invited to participate in the diagnostic interview.  If the 
respondent (mother or sibling) described symptoms in a birth cohort member, the respondent was asked 
if he or she would be willing to have the study contact the affected family member about participation in 
the study. If the respondent agreed, the affected cohort member was contacted by letter and invited to 
participate.   
 
Diagnostic protocol 
 Accurate diagnosis of BP is critical to understanding its causes. A number of prior studies, as 
noted above, have suffered from poor diagnostic specificity of BP, grouping a number of illnesses into 
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catch-all categories such as “affective disorders.” The current research benefits from the careful 
diagnostic assessment and inclusion of confirmed cases of BP.  
 A total of 214 subjects (48% of those ascertained) were interviewed using the Structured Clinical 
Interview for DSM-IV TR (SCID). The reasons that some subjects were not interviewed were: 100 could 
not be contacted, 80 refused or failed to keep the appointment, and 54 who could not be interviewed 
because he or she had died, were incarcerated, permission from the physician could not be obtained, or 
because the person was too psychotic or mentally disabled.   
 Study interviewers had a minimum of a master’s degree in a mental health field and were trained 
to reliability on the SCID. DSM-IV-TR diagnoses including diagnostic qualifiers representing subtypes of 
BP were systematically assigned by consensus of three experienced clinicians (psychiatrists/Ph.D. 
psychologist), based on review of the SCID and medical records. This yielded 72 total BP cases. Among 
those interviewed, consensus diagnoses of non-BP disorders were also assigned: there were 61 cases of 
SZ and other schizophrenia spectrum disorders, 62 cases of major depressive disorders, and 19 cases 
with other diagnoses. These non-BP categories were not included in the present study. Although unipolar 
major depressive disorder was not included in the screening procedure, the diagnostic protocol enabled 
us to exclude subjects with database diagnoses of BP and/or psychotic disorders who were found instead 
to have unipolar depressive disorder in accord with structured research criteria.   
 
Ascertainment from PDS I study 
 Additional cases of BP had been ascertained through Kaiser records by an earlier study (Prenatal 
Determinants of Schizophrenia I, PDS I) were included in the present study (Susser, Schaefer et al. 
2000). Although the purpose of PDS I was to identify SZ and other schizophrenia spectrum disorder 
cases, BP cases were also diagnosed by interview in that study. The protocol for the PDS I included the 
same electronic linkages with the Kaiser inpatient, outpatient, and pharmacy databases, and utilized the 
same ICD-9 diagnostic codes (295-298).  Ascertainment covered the period from 1981-1998. The only 
other differences in the screening methods are that the PDS I did not include review of pharmacy records 
for treatment with mood stabilizers, and the PDS I included a second screening step, which involved 
psychiatrist review of abstracted data from inpatient/outpatient records for symptoms of psychosis. The 
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Diagnostic Interview for Genetic Studies (DIGS), rather than the SCID, was used for interviewing potential 
subjects in the PDS I. There were 23 BP cases diagnosed in the PDS I study.  
 In total, then, 95 people with BP were diagnosed following ascertainment from all sources and 
clinical interview. 
 After complete description of the study to the subjects, written informed consent was obtained. 
The study protocol was approved by the Institutional Review Boards of the New York State Psychiatric 
Institute and Kaiser.  
 
Control Selection 
 In order to ensure that controls would have been equally likely (as their matched cases) to be 
ascertained if they had been treated for BP in Kaiser or ABHCS, controls were matched to cases on 
membership in Kaiser (for cases ascertained through Kaiser records) or residence in Alameda County 
(for cases ascertained through ABHCS or by CHDS mailing survey) in the year the case was first treated 
as reported in the SCID. For Kaiser, membership in the plan at that time was used for control matching, 
since cohort members would have been documented in Kaiser databases if they sought care for BP. The 
DMV was used to ensure place of residence at the time of diagnosis for cases treated by ABHCS and 
those identified from the mailed survey, since these subjects would have been the population at risk for 
treatment at same time. The vast majority of the subjects who received the mailing were Alameda County 
residents. 
 Control matching criteria included: date of birth (+/- 30 days), sex, and availability of maternal 
archived sera (for serologic studies). A maximum of an 8:1 ratio of controls to cases was achieved, as it 
represented the maximum number of controls that could be successfully matched to cases on all criteria 
and to maximize statistical power. 
 Exclusion criteria (prior to matching) were: all of the CHDS cohort members who screened 
positive for potential bipolar or psychotic disorders (N=376) and siblings of those cases; potential controls 
who belonged to Kaiser at the time of case ascertainment were excluded from the control pool for cases 
identified from ABHCS or the cohort mailing; and siblings of selected controls were excluded from further 
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control selection, so that all controls were independent observations, each representing a single family or 
pregnant woman.   
 This protocol yielded 754 matched controls. 
 
Measurement 
Method for T. gondii 
 The CHDS aimed to obtain maternal serum for each pregnancy during each trimester. At each 
blood draw, 30 cc were collected and spun, dividing the sera into four aliquots of approximately 2 cc 
each. The samples were transferred to glass vials and stored frozen at -20 degrees since being obtained. 
One-two cc of maternal sera were provided for each time point during pregnancy for each case and 
control. These serum samples have been successfully analyzed now for a number of biomarkers, 
including for T. gondii. Biomarker evidence, obtained prospectively, is the gold standard for assessing the 
exposure and ensuring pre-birth maternal exposure. 
 The T. gondii assays were performed in the Toxoplasma Serology Laboratory at the Palo Alto 
Medical Foundation Research Institute, which is the T. gondii reference laboratory for the US (Montoya 
2002). Three assays were used. The first two concern the assessment of T. gondii IgG antibody titer. 
Samples were screened for the presence of IgG antibody titer and then the Sabin-Feldman dye test 
(Sabin and Feldman 1948) was performed in the samples that screened positive. T. gondii IgM antibody 
was also assayed, which is indicative of recent infection, using the double sandwich enzyme-linked 
immunosorbent test (IgM-ELISA). The seroprevalence of IgG antibody was 22/123 (17.9%) in controls. 
This value is similar to the 17.5% seroprevalence found in a large previous study of T. gondii in 
reproductive-aged women (Jones, Kruszon-Moran et al. 2001). None of the control serum samples tested 
by ELISA were positive for T. gondii IgM antibody. This was not unexpected, as T. gondii IgM antibody is 
indicative of active infection within 2 months of the blood draw, which is unlikely given the low incidence 
of toxoplasmosis during this time frame (Remington 2011).  
 For the primary analysis, T. gondii IgG for the last serum sample drawn for each pregnancy (late 
third trimester/perinatal) was analyzed. This replicates the methods used in the PDS study of T. gondii 
and SZ (Brown, Schaefer et al. 2005). The third trimester/perinatal period of gestation provides the 
   
51 
 
greatest opportunity to detect T. gondii infection if it occurred at any time during pregnancy because even 
an infection that occurred early in pregnancy will result in elevated IgG antibodies for many months or 
years following infection (Remington 2011).  
 The dye test IgG titers was classified into three groups: negative (<1:16) (reference), moderate 
titer (1:16-1:64), and high titer (≥1:128). We hypothesize that the high IgG titer group will have an 
increased risk of BP.  
 The T. gondii analyses include 85 cases, matched 1:2 with controls, for whom the serological 
assay for T. gondii was available. T. gondii exposure is categorical (high, medium, and unexposed). This 
study has sufficient power to detect a moderate association (OR = 2.7, power of .8 and p = .05), similar to 
the effect size previously observed in the SZ study for T. gondii in this cohort (Brown, Schaefer et al. 
2005), and thus, a reasonable a priori hypothesis.  
 T. gondii has been assayed from the maternal sera which were obtained for each gravida in the 
cohort. The association between T. gondii and BP, using the IgG results was estimated using conditional 
logistic regression. Results are reported as hazard ratios because of the incidence density sampling for 
the nested case-control. Maternal age (<35 [reference], ≥35), maternal ethnicity (Caucasian [reference], 
African American, other), maternal educational achievement (defined as maternal education: <high 
school, high school only [reference], some college/college graduate), parity, and gestational age of the 
serum sample (in days after last menstrual period) will be considered as potential confounding variables. 
Fetal hypoxia was considered as a potential confounder but no reliable measure of it was available in 
these data. Any of these potential confounders which is associated with exposure and outcome at a 
probability greater than 0.1 will be controlled in the analyses. A previous study examining the association 
between T. gondii and SZ tested similar potential confounders, finding only maternal age to be associated 
with T. gondii titer level (Brown, Schaefer et al. 2005). Yet, others have hypothesized a host of potential 
confounders related to T. gondii (Mortensen, Pedersen et al. 2011), and epidemiological surveys have 
reported differences by job type, SES, education level, and ethnicity (Jones, Kruszon-Moran et al. 2001), 
suggesting that these potential confounders be considered. Each of the above specified covariates will be 
tested for their possible association with both the exposure (T. gondii) and the outcome (BP). 
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Method for oxytocin  
 Oxytocin administration to induce labor was contemporaneously documented in medical charts in 
the CHDS and systematically abstracted from the medical records by the CHDS. The CHDS noted 
oxytocin in four separate fields which have been combined to construct a dichotomized variable: oxytocin 
versus no oxytocin. The analyses will consider whether oxytocin exposure during maternal labor is 
associated with BP. 
 Conditional logistic regression models will be used for the matched case-control analyses as 
described above. The oxytocin analyses include all 93 cases, matched 1:8 with controls, with 9 controls 
missing. This gives sufficient power to observe a moderate effect (OR = 2.4, power of .8 and p = .05). 
Gestational age and maternal psychiatric history will be tested as a potential confounders since both 
could be related to oxytocin use and BP. Potential confounders, as described above, will also be 
controlled when associated with exposure and outcome at a probability greater than 0.1.  
 
Method for prolonged labor 
 The CHDS documented length of labor contemporaneously to each birth by noting time from 
onset of labor to delivery as well as second stage to delivery. Using the current definitions of prolonged 
labor, equal to or greater than six hours for first stage, and equal to or greater than two hours for second 
stage for first births and equal to or greater than one hour for additional births (ACOG 2003, Zhang, 
Landy et al. 2010, Spong, Berghella et al. 2012), this variable was dichotomized to prolonged versus not 
prolonged. In addition, labor time was examined as a continuous variable using the time noted in the 
medical charts in the CHDS. Each of the stages and the continuous length of labor was tested for an 
association with BP using conditional logistic regression. 
 Prolonged labor could be an antecedent to oxytocin in that women with longer labors might be 
more likely to be induced with oxytocin, which in turn increases the risk for BP. Alternatively, it could 
confound the relationship between oxytocin and BP in that longer labor shares a common cause with 
oxytocin to induce. Therefore, the association between prolonged labor and BP are tested, as are the 
association between prolonged labor and oxytocin. These analyses are a method for testing the whether 
the potential oxytocin relationship to BP is confounded by or the result of labor length. 




Method for analgesics 
 Analgesics were coded by drug given in the CHDS and here, a dichotomous variable for any 
analgesic versus none was constructed for analyses. Testing a potential role of analgesics, as a 
confounder or for possible interaction with oxytocin, could provide support for the specificity of oxytocin. It 
is possible that women who receive oxytocin are more likely to also be given an analgesic. It is also 
possible that being given any drug intervention at a late stage of pregnancy could increase the risk for 
BP. To test for this, analgesics will be treated first as a potential confounder and then tested for possible 
multiplicative or additive interaction with oxytocin and risk of BP. Conditional logistic regression is used for 
these analyses. 
 
Method for delivery type 
 Delivery type was documented by the CHDS as well. It is possible that labor complications lead to 
caesarean as a medical intervention. This may also be a reason that oxytocin to induce labor was used. 
In this way, labor complications may be an unmeasured common cause of both delivery type and 
oxytocin. Delivery type is analyzed as a potential confounder, similar to the demographic covariates which 
are tested for potential confounding. Delivery type is presented as a separate comparison because of its 
temporal association with the use of oxytocin in the birth process. A dichotomous comparison between 
caesarean and vaginal delivery and BP disorder was analyzed. Again, conditional logistic regression was 
used to model the associations.  
 
Results 
 First, for the BP case-control, potential confounders were assessed by comparing differences 
between cases and controls. As can be seen in Table 8, none of the potential demographic confounders 
is associated with case status with the exception of maternal race. However, maternal race was not 
associated with oxytocin (for African-Americans, p = 0.90; for “other,” p = 0.94) nor with BP (for African-
Americans, p = 0.70; for “other,” p = 0.2), and maternal psychiatric history was not associated with 
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Table 8: Demographic comparison of cases and controls 
 Bipolar Cases  
(N = 94) 
Controls  
(N = 746) 
P value 
Maternal age at child's birth, Mean (SD) 27.3 (6) 28.0 (6) 0.32 
Maternal education, N (%)   0.85 
< High school 18 (21) 128 (19)  
High school graduate 32 (37) 271 (39)  
Some college or college graduate 36 (42) 293 (42)  
Maternal race, N (%)   0.07 
white 64 (69) 425 (58)  
African-American 24 (26) 215 (29)  
other 5 (5) 92 (13)  
Paternal education N (%)   0.51 
< High school 12 (14) 134 (20)  
High school graduate 26 (32) 192 (28)  
Some college or college graduate 44 (54) 350 (52)  
Paternal race, N (%)   0.14 
white 55 (70) 387 (59)  
African-American 19 (24) 189 (29)  
other 5 (6) 79 (12)  
Maternal psychiatric history (any), N (%) 24 (25) 132 (18) 0.07 
Birthweight in grams, Mean (SD) 3374 (21) 3289 (17) 0.17 
Gestational age in days, Mean (SD) 281 (16) 280 (14) 0.33 
 
Results for T. gondii 
 For the 255 samples tested, 35 were high IgG titer and 20 were moderate IgG titer. Table 9 
displays the comparison between low titer (the referent) and moderate and high titers for risk of BP. 
Neither high nor moderate titers were associated with BP. None of the potential confounders were found 
to differ significantly between cases and controls. 
 




Low Titer  Referent -- 
Moderate Titer 1.43 (0.491, 4.171) 
High Titer 1.6 (0.738, 3.478) 
 
Discussion of T. gondii 
 This finding is consistent with that reported by Mortensen et al (Mortensen, Pedersen et al. 2011), 
and confirms their result in an independent birth cohort. That study, as noted, analyzed dried blood spots 
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on filter paper obtained from the infant and not maternal sera obtained during pregnancy. This study used 
maternal sera drawn at birth but reaches the same result.  
 Therefore, distinct from the risk that T. gondii poses for later life SZ (Brown, Schaefer et al. 2005), 
it does not appear that prenatal exposure to T. gondii increases the risk of offspring BP. As the 
mechanisms by which T. gondii increases the risk of SZ become better elucidated, it may be possible to 
further differentiate this risk as a potential cause for SZ but not BP. However, this non-significant result 
may reflect a lack of power. The effect size does increase as the titer increases, and the confidence 
interval is smaller for the high titer, suggesting a dose-response effect. Further testing of T. gondii in 
larger samples is warranted. 
 
Results for Oxytocin 
 Of 831 subjects, 34 received oxytocin to induce labor: 8 cases and 26 controls. As shown in 
Table 10, oxytocin is associated with a 2.45 times increased risk of BP in adulthood (HR = 2.45, CI: 1.08, 
5.58). Controlling for gestational age has almost no effect on the finding and controlling for maternal 
psychiatric history may slightly enlarge the effect of oxytocin.  
 




Oxytocin 2.45 (1.08, 5.58) 
Oxytocin controlling for 
gestational age 
2.44 (1.07, 5.55) 
Oxytocin controlling for 
maternal psychiatric history 
2.99 (1.08, 8.3) 
 
Results on the falsification of the oxytocin finding 
 In order to further parse the oxytocin finding, the three potential alternative explanations were 
tested: prolonged labor, analgesics, and delivery type. First, prolonged length of labor as a continuous 
time, from time of active onset to birth, was not associated with BP (p = 0.41) in an unadjusted model. 
Prolonged first stage of labor was not associated with BP (p = 0.1) in an unadjusted model. Prolonged 
second stage of labor was not associated with BP (p = 0.064) in an unadjusted model. However, no 
people who had prolonged second stage labor also received oxytocin. Continuous labor length was 
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associated with 1.7 times increased use of oxytocin (parameter estimate = 0.32, chi square = 7.85, p 
=0.005), but the increase is for mothers with shorter labor.  
 Second, for 840 births, 748 mothers received an analgesic. Analgesics were not associated with 
BP (chi-square = 0.21, p = 0.65). To test the hypothesis that analgesics could interact with oxytocin, a 
model was tested which included a cross-product of those two exposures. The interaction term was not 
associated with BP (p = 0.988). However, only a single person who received oxytocin did not also receive 
an analgesic. This means that off support data makes the analysis of interaction in this case-control study 
not feasible. Third, for delivery type, 795 had vaginal births and 42 had cesarean births. Neither cesarean 
nor vaginal births were associated with BP (for both variables, p = 0.99).  
 
Discussion of oxytocin 
 Oxytocin to induce labor is associated with a 2.45 times increased rate of later life BP. Controlling 
for gestational age, which could be related to oxytocin because longer gestation might lead to an 
increased use of oxytocin, made no difference in the effect size of oxytocin on BP. Controlling for 
maternal psychiatric history may increase the observed effect slightly. 
 The observed effect appears to be directly related to oxytocin as a drug, not as a proxy for other 
complications. In an effort to more clearly test the specificity by which oxytocin is associated with BP, and 
to rule out some potential avenues of confounding, delivery type, analgesics, and duration of labor were 
each tested. Delivery type, which might have reflected a similar type of labor complication resulting in 
medical intervention (e.g., where labor complications are a common cause), was not associated with BP 
or with oxytocin. This supports the conclusion that oxytocin's effect is not a generic proxy for labor 
complications. Analgesics, which might reflect a non-specific effect of drug interventions during labor or 
share a common cause with oxytocin, was also not associated with BP. Although it is not possible to test 
for interaction in this study, Oscarsson et al had similarly tested whether analgesics played a role in poor 
outcomes associated with induced labor and also found that they did not (Oscarsson, Amer-Wahlin et al. 
2006). Again, this supports the conclusion that the effect of oxytocin is specific. 
 Third, prolonged labor, which conceptually could be associated with an increased use of oxytocin 
to induce labor, did not act as hypothesized. It is associated with a 1.7 times increased use of oxytocin, 
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but for mothers with shorter rather than longer duration of labor. Moreover, no subjects with prolonged 
second stage of labor received oxytocin to induce labor, which runs counter to the hypothesis that the 
longer second stage would lead physicians to induce more often.  
 These findings suggest a specific effect of oxytocin on the risk for BP. As noted above, oxytocin 
has been reported to increase the risk of neonatal intensive care and lower Apgar scores (Oscarsson, 
Amer-Wahlin et al. 2006, Selo-Ojeme, Rogers et al. 2011), is associated with an increased risk of ADHD 
(Kurth and Haussmann 2011), and an increased risk for autism in a large cohort from North Carolina 
(Gregory, Anthopolos et al. 2013). Kurth and Haussmann suggested that future research should consider 
whether the combination of oxytocin and an analgesic best explained the increased risk of psychiatric 
illness because those who received oxytocin were more likely to be given an epidural anesthesia in their 
sample (Kurth and Haussmann 2011). The current study does not support the hypothesis that analgesics 
and oxytocin interact to increase the risk for BP, but instead indicate that oxytocin, and not analgesics, act 
to increase risk.  
 It is usually hypothesized that the mechanism by which maternal oxytocin exposure may affect 
offspring is fetal hypoxia, restricted neural blood flow, and increased fetal bilirubin (Drew and Kitchen 
1976, Connor and Seaton 1982). This study does not rule that hypothesis out, but it does suggest that the 
mechanism may be more specific to oxytocin itself.  
 Uterine contractions during parturition are prompted by endogenous maternal oxytocin, released 
from the hypothalamus and pituitary (Maggi, Baldi et al. 1994, Brunton, Russell et al. 2013). Endogenous 
oxytocin also plays a critical role in the maternal stress response, a response which is suppressed during 
pregnancy and birth to avoid premature labor from emotional and physical stressor exposures, such as 
immune challenges from viral exposure or social stress (Brunton and Russell 2008, Brunton and Russell 
2011). Disruption of the maternal stress response system, which exogenous oxytocin to induce labor 
could plausibly prompt, has been shown to affect fetal neuronal development, neural plasticity, and 
myelination (Brunton and Russell 2011, Duthie and Reynolds 2013). Further, endogenous maternal 
oxytocin signals a temporary GABA switch in the fetus, from excitatory to inhibitory, in preparation for 
labor (Tyzio, Cossart et al. 2006, Khazipov, Tyzio et al. 2008, Ceanga, Spataru et al. 2010); this switch is 
thought to protect the fetal brain, but may become excessive with the addition of exogenous oxytocin 
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because the neuroprotective effect occurs only within a narrow range of oxytocin expression (Ceanga, 
Spataru et al. 2010). During brain development, GABA, and its precursor glutamate, affect neuronal 
migration, differentiation, and survival; GABA maturation continues through adolescence in normal 
development (Catts, Fung et al. 2013); and, alterations of the GABA neurotransmitter system have been 
found in people with BP (Benes, Lim et al. 2007, Gigante, Bond et al. 2012). In addition, high 
concentrations of maternal oxytocin just prior to labor increase the risk for fetal hypoxia-ischemia 
(Ceanga, Spataru et al. 2010).  
 Although plausible, these findings require confirmation and further testing before the mechanism 
can be meaningfully tested. That research suggests a plausible biologic mechanism for the observed 
effect of oxytocin, and because the effects observed appear to be specific to oxytocin as a chemical 
agent rather than as a proxy or place-holder, replication is warranted. Finally, the increased use of 
oxytocin has been associated with neonatal morbidity generally (Oscarsson, Amer-Wahlin et al. 2006, 
Buchanan, Patterson et al. 2012), but whether the increased use is associated with an increased 
incidence of BP is not known and should also be considered.  
 
Conclusion 
 In summary, the results of this study of the prenatal and perinatal risks for BP are that T. gondii 
was not associated with later BP. This differs from the findings for SZ, in which an association is 
observed. As a result, this may suggest potential causal differences between BP and SZ, but the small 
sample size may mean that this study is underpowered to have observed the hypothesized effect. 
 In contrast, oxytocin to induce labor is associated with BP, and the association appears to be 
specific to the chemical agent itself. Oxytocin has not been studied as a risk factor for SZ and further 
research is needed as a result, but this finding corresponds with other recent research which indicates 
that oxytocin is a risk for autism and ADHD. 
 In conclusion, this research supports the neurodevelopmental hypothesis in the sense that a 
specific early life exposure has been found to alter the course of neurodevelopment. It lends some 
specificity to the search for putative causes and mechanisms of BP.  
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Paper 3: Premorbid cognition, environmental exposures, and Bipolar disorder (BP) 
 One key pillar of support for the neurodevelopmental hypothesis of schizophrenia (SZ) is the 
evidence of cognitive impairment during the premorbid and prodromal periods (Keshavan, Kennedy et al. 
2004, Reichenberg and Harvey 2007, Woodberry, Giuliano et al. 2008, Mesholam-Gately, Giuliano et al. 
2009, Consortium 2013, Olvet, Burdick et al. 2013). For instance, a nested case-control study of SZ 
drawn from the Child Health and Development Study (CHDS) birth cohort, compared childhood cognitive 
performance as measured by the Peabody Picture Vocabulary Test (PPVT) given at ages 5 and 9-11, 
and re-administered in adulthood, to examine the course of cognitive functioning over 33 years. This 
study found a ten point difference in the early childhood PPVT, with those who would later develop SZ 
performing more poorly than the matched controls. In adulthood, the gap in performance was wider, with 
those who had developed SZ scoring 15 points below the controls (Kremen, Vinogradov et al. 2010). The 
ten point difference observed in childhood scores is consistent with the neurodevelopmental hypothesis of 
SZ. 
 Evidence of premorbid and prodromal cognitive impairment in BP would similarly support the 
neurodevelopmental hypothesis for BP. Numerous studies and meta-analyses have reported cognitive 
impairments in all phases of illness, including the premorbid and prodromal periods of developments, for 
the high risk, at first onset, in euthymic states, and for each type of BP: BP I, BP II, BP NOS, BP with and 
without psychotic features (Bearden, Hoffman et al. 2001, Quraishi and Frangou 2002, Reichenberg, 
Weiser et al. 2002, Martinez-Aran, Vieta et al. 2004, Savitz, Solms et al. 2005, Daban, Martinez-Aran et 
al. 2006, Daban, Martinez-Aran et al. 2006, Robinson, Thompson et al. 2006, Torres, Boudreau et al. 
2007, Arts, Jabben et al. 2008, Goodwin, Martinez-Aran et al. 2008, Bora, Yucel et al. 2009, Kurtz and 
Gerraty 2009, Reichenberg, Harvey et al. 2009, Stefanopoulou, Manoharan et al. 2009, Bearden, 
Woogen et al. 2010, Harvey, Wingo et al. 2010, Latalova, Prasko et al. 2011, Mann-Wrobel, Carreno et 
al. 2011, Pol, van Baal et al. 2012, Bourne, Aydemir et al. 2013, Hill, Reilly et al. 2013, Lim, Baldessarini 
et al. 2013). Cognitive deficits are observed in the domains of executive functioning, verbal learning, 
verbal memory, sustained attention, and psychomotor speed. The effect sizes are moderate and large in 
these domains. These studies are often used to support the notion that cognitive impairment is a trait of 
those who develop or have BP.  
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 Some, but not all, population based studies, many of them using conscript testing, have reported 
premorbid cognitive impairment. These draft board neuropsychological batteries lack the specificity and 
breadth of a complete functional assessment, although they do provide useful population based 
information on a testing battery that mimics IQ assessments. One large Danish draft board study reported 
small IQ difference for both BP and unipolar depression compared with the general population, with no 
significant differences between illnesses (Sorensen, Saebye et al. 2012). A second Danish draft board 
study observed small deficits in IQ for people who developed affective disorders (as well as 
schizophrenia; non-schizophrenic, non-affective psychotic disorder; neurotic or stress disorder; and 
personality disorders) compared with population controls (Urfer-Parnas, Mortensen et al. 2010). And, a 
third Danish draft board study of all men born in 1953, compared testing at ages 12 and 18 for those who 
later developed BP, also reporting impaired cognition compared to those without BP, but the sample size 
(N=16) is reported to be too small to offer stable results (Osler, Lawlor et al. 2007). A more recent 
analysis of four Swedish birth cohorts compared trend data for testing at ages 13 and military induction 
testing at age 18. They reported that the 18 subjects with BP performed better than the population at both 
time points on verbal, spatial, and inductive reasoning (MacCabe, Wicks et al. 2013). In contrast, a 
Finnish population based cohort study, analyzing conscript testing at ages 18-19, reported that worse 
premorbid performance on a test of visuospatial ability predicted later onset BP (Tiihonen, Haukka et al. 
2005). 
 Population based studies that assess cohorts on other types of cognitive testing than the 
conscript studies tend to indicate deficits in specific domains. In a prospective study which followed 
children into adulthood, children tested between ages 3 and 11 who later developed bipolar mania, had 
receptive and expressive language skills that varied between testing periods compared with controls 
(expressive language was higher at age 3, lower at ages 5 and 7, and higher at age 11; receptive 
language was lower at age 3, higher at 5 and 7, and lower at age 11; IQ was slightly higher at age 7 and 
lower at age 11), and they had more behavioral difficulties (Cannon, Caspi et al. 2002). This study 
included only 20 people who developed mania in adulthood through age 26, and none of the scoring 
differences reached statistical significance. Another prospective study, this one of children at high risk for 
BP followed for 23 years, reported that the 9 people who developed BP had lower IQ scores than those 
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who developed unipolar (n = 22) and those without mood disorder (n = 64), although all the scores were 
within the normal range (Meyer, Carlson et al. 2004).  In addition, they found that those who developed 
BP performed significantly worse on executive functioning measures prior to onset. 
 High risk studies have tended to find differences between those who develop BP and those who 
do not. An exploratory high risk for psychosis study prospectively followed and compared 16 people who 
converted to BP with 46 who did not convert to psychosis, and to 66 healthy comparison subjects, 
matched on age and sex (Ratheesh, Lin et al. 2013). At baseline, the clinical characteristics of all those at 
high risk were similar; subjects who later developed BP had lower full scale IQ scores compared with 
controls (approximately twelve points lower than healthy controls and four points lower then other high 
risk subjects), and performed significantly worse on a measure of executive functioning. Another 
comparison of high risk subjects, this one comparing pre-conversion functioning for 8 subjects who later 
converted to BP, 24 who later converted to SZ, and 115 non-converters, found that at baseline the BP 
subjects had IQ scores approximately 10 points lower than non-converters, although this was non-
significant (Olvet, Stearns et al. 2010). Although reporting that the BP group performed worse than non-
converters on other neuropsychological tests, and that they also demonstrated more variance in scoring, 
the authors note that the study was underpowered. 
 School performance reflects another arena in which to consider premorbid functioning. A twin 
study of school success observed that those who later developed BP had fewer years of education and 
worse performance compared with matched, control twins (Vonk, van der Schot et al. 2012), and this 
finding is also reported in case-control studies (Glahn, Bearden et al. 2006). Cannon et al demonstrated 
worse premorbid sociability, adjustment, and schooling for those who later developed BP (Cannon, Jones 
et al. 1997). However, others have reported that both low and high premorbid school performance is a 
risk factor for BP based on a longitudinally followed, nationally representative cohort (MacCabe, Lambe et 
al. 2010). 
 In summary, cognitive functioning prior to the onset of illness, one key pillar of the 
neurodevelopmental hypothesis, tends to demonstrate domain specific impairments on average, with 
some worse and some superior performance on global measures such as IQ. The effect sizes are larger 
for people during the prodromal period then during the premorbid period, but none of the effect sizes are 
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as large as those observed in people who later develop SZ. A review of population based studies 
concluded that the evidence of premorbid cognitive impairment does not yet support a conclusion that 
such impairments define a trait of later BP (Kravariti, Kane et al. 2009). One limitation of the premorbid 
studies has been the small sample sizes and the narrow test batteries used prospectively for assessment. 
Further investigation of the mixed evidence of premorbid cognitive functioning in those who later develop 
BP may improve our understanding of whether BP should be considered a neurodevelopmental illness. 
 The BP nested case-control study drawn from the CHDS birth cohort provides an opportunity to 
further test the premorbid cognitive functioning of those who later develop BP. Prospectively administered 
cognitive testing in this well defined birth cohort, and the availability of large numbers of children tested, 
permits analyses of premorbid functioning without retrospective biases. These data also allow for testing 
of the relationship among prenatal and perinatal exposures and cognition, and the relationships between 
those early life exposures, cognitive performance in childhood, and later life BP.  
 Childhood diagnostic measures included the Peabody Picture Vocabulary Test (PPVT) and the 
Raven Matrices (Raven). The PPVT is a well-known, commonly used test which estimates receptive 
verbal ability. Alternate form reliability of the PPVT is estimated to be r = .77 (Dunn 1965). The examinee 
is shown a plate with four pictures, the examiner speaks a word describing one of the four, and the 
examinee selects the correct picture either by speaking or pointing. The test manual indicates that it can 
be used with children as young as two and a half years old, and the instrument does not require reading, 
writing, or verbal ability. The PPVT was originally normed on 4012 children between the ages of 2 and 18, 
with a total of 133 aged 5 and 962 between ages 9-11 (Dunn 1965). In the CHDS, the PPVT was given to 
3,413 children at age 5 and 3,737 at ages 9-11. The size of the birth cohort allows for cohort specific 
norming of the PPVT, rather than relying on the much smaller age specific standardization sample 
conducted for the original publication of the instrument. 
 The Raven instruments are cognitive tests of visual-spatial processing, inductive reasoning, 
relational reasoning, and problem solving. Test-retest reliability of the Raven for children under age 13 is 
estimated to be r = .88 (Raven 1958). Each question displays a pattern with a block missing, and four 
choices to choose from, one of which accurately completes the pattern. It is commonly described as well 
correlated with standard IQ test measures, primarily because of its correlation with measures of fluid 
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intelligence. The Raven, or tests which mimic the design of the Raven, have been used in numerous tests 
batteries of premorbid and post onset cognition in those who later developed psychotic disorders, with  
impaired performance on the Raven consistently being associated with psychosis (Berman and 
Weinberger 1990, Welham, Scott et al. 2010, Zanelli, Reichenberg et al. 2010). Worse performance on 
the Raven has been reported for those who later developed SZ compared with controls (Caspi, 
Reichenberg et al. 2003, Cannon, Moffitt et al. 2006). Zanelli et al (2010) used the Raven as a measure 
of executive functioning in a study of first episode psychosis and found that, although all first episode 
psychosis groups were impaired compared with healthy controls, those with SZ, depressive psychosis, 
and other psychosis performed substantially worse than those with BP (Zanelli, Reichenberg et al. 2010).  
 The CHDS prospectively documented a number of prenatal and perinatal exposures, including 
gestational influenza and oxytocin, and obtained maternal sera for each pregnancy which was tested for 
T. gondii. Each of these exposures may have a negative effect on cognition. First, maternal infections 
during pregnancy, including influenza, are associated with cognitive impairment in offspring who develop 
SZ when they reach adulthood (Brown, Vinogradov et al. 2009). Exposure to maternal influenza has been 
reported to affect childhood cognition in some specific domains in those who develop SZ, although not in 
controls (Ellman, Yolken et al. 2009). It has also been suggested that men potentially exposed in utero to 
the main outbreak of pandemic flu in the winter of 1968-9 in Norway, performed significantly more poorly 
on military conscript testing compared to those born in non-flu years (Eriksen, Sundet et al. 2009). They 
found that scores for men born 6 to 9 months after the epidemic were lower than scores for the men born 
in the same months, but in the years before and after the epidemic. The study did not have confirmation 
of exposure to influenza in individual pregnancies, however. A similar result, although using less 
standardized testing measures at ages 7 and 11, has also been reported from the National Child 
Development Study in the UK (Kelly 2011). Controlled administration of maternal influenza to pregnant 
rhesus monkeys did affect offspring neurodevelopment, specifically reducing gray matter in the cortex 
and white matter in the parietal cortex (Short, Lubach et al. 2010), providing animal model support for 
influenza as a causal agent which impairs cognition. Similarly, maternal viral infection in a number of 
animal species has been associated with behavioral and cognitive impairments in offspring (Meyer and 
Feldon 2010). The CHDS prospectively documented exposure to influenza during pregnancy. 
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 Second, prenatal exposure to T. gondii’s and the possible association with impaired cognition, 
and its association with SZ, makes it an important antecedent to test as part of considering whether BP is 
neurodevelopmental as well as for better understanding the potential mechanisms of BP. Much of the 
prior evidence is either ecological or based on measures of adult exposure. Prenatal exposure, however, 
would affect development, thereby offering evidence of a developmental cognitive effect. The 
Collaborative Perinatal Project, a multisite, prospective study of more than 22,000 births, reported on 
childhood cognitive outcomes at age 7, finding that the highest maternal T. gondii titer was associated 
with a thirty percent increased risk of offspring IQ below 70 and with neurological soft signs (Sever, 
Ellenberg et al. 1988). The mechanism by which the parasite proliferates, specifically affecting the central 
nervous system, suggests that prenatal exposure is likely an important period of risk for neuronal 
maldevelopment. Thus, the purported mechanism by which T. gondii could affect neurodevelopment, both 
impairing cognition and increasing risk for psychiatric illness, can be analyzed in this case-control study 
directly to assess the neurodevelopmental effects of exposure.  
 Third, induction with oxytocin has been associated with an increased risk BP (above), ADHD 
(Kurth and Haussmann 2011), and autism (Gregory, Anthopolos et al. 2013). Oxytocin, as measured in 
adults and in animal models, has been associated with impairments in learning, attention, and memory, 
and oxytocin is reported to reduce cognitive ability in experimental models (Demitrack and Gold 1988). 
Although some obstetric complications have been associated with childhood cognitive deficits (Seidman, 
Buka et al. 2000, Leitner, Fattal-Valevski et al. 2007), no prospective population based studies of oxytocin 
have been identified.  
 
Methods: 
 The Child Health and Development Study (CHDS) is a large, representative birth cohort, 
containing 19,044 live births. This cohort has been followed prospectively, with prenatal serologic 
samples obtained during pregnancies, perinatal measures obtained during routine medical care, 
childhood cognitive assessment performed at ages 5, 9-11, and 15-17 on subsets of the birth cohort, and 
psychiatric diagnoses confirmed in adulthood. Using a nested case-control design to obtain all BP cases 
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and matched controls from the CHDS, this research investigates the relationship between serologically 
obtained prenatal exposures and birth complications, early childhood cognition, and onset of BP. 
 Cases and controls for the Prenatal Factors and Bipolar Disorder Study were drawn from the 
CHDS birth cohort (van den Berg, Christianson et al. 1988). The CHDS recruited nearly all pregnant 
women receiving obstetric care from the Kaiser Permanente Medical Care Plan, Northern California 
Region (Kaiser) in Alameda County, California between 1959 and 1966. Contemporaneously completed 
medical records, maternal interviews, child assessments, and other sources were generated 
prospectively during the course of pre and perinatal medical care provided by Kaiser. Kaiser reflects the 
population of the Bay Area of California at the time, providing care to approximately 30% of the population 
of Alameda county, with some underrepresentation at both the extremes of income. This birth cohort has 
been extensively studied for prenatal and other early developmental risk factors for SZ (Susser, Schaefer 
et al. 2000). 
 Two analyses are reported here. The first examines premorbid cognition and the risk of BP in the 
nested case control birth cohort. The second investigates the associations among gestational exposure to 




 People with potential DSM-IV BP, which included BP I, BP II, BP NOS, and BP with psychotic 
features, were ascertained by screening procedures which used data from three sources: Kaiser’s 
electronic medical records database, the Alameda County Behavioral Health Care Services (ABHCS) 
database, and a mailing to the entire living CHDS birth cohort (mothers and children). This approach 
sought to maximize ascertainment of individuals with BP. CHDS cohort members who belonged to Kaiser 
when first treated would have been ascertained from this source. Subjects who left Kaiser prior to the first 
treatment of BP and who did not have other health insurance, but who still lived in Alameda County, 
would likely have been treated by ABHCS and therefore ascertained. Subjects who were not ascertained 
by these two approaches were ascertained by a mailed survey to the entire cohort. 
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 The ascertainment process identified 448 subjects who potentially met the criteria for BP and 
psychotic disorder. 
 
Ascertainment of Kaiser subjects 
 Subjects with potential BP (and other psychotic disorders) were identified by screening Kaiser’s 
inpatient and outpatient databases. Computerized record linkages between CHDS and Kaiser identifiers 
were conducted on these databases. The inpatient database included all psychiatric hospitalizations of 
Kaiser members regardless of the hospital at which treatment is received. This covered the period from 
1981-2010. Those with discharge diagnoses of ICD-9 295-298 from the Kaiser inpatient database were 
considered as potential BP subjects. A database of outpatient treatment was introduced in 1981, but did 
not contain searchable codes for diagnoses until 1995. Potential BP cases from the outpatient database 
were considered to screen positive if they received ICD-9 diagnoses of 295-298 excluding unipolar major 
depressive disorder. Case ascertainment also used the Kaiser outpatient pharmacy database, which 
commenced in 1992. Cases screened positive based on prescriptions for mood stabilizing medications 
used in the treatment of BP (lithium, carbamazepine, valproic acid). Before contacting subjects who were 
currently enrolled in Kaiser, the subject’s treating psychiatrist was contacted, informed about the study, 
and asked to approve contact with the subject to seek his/her consent to participate. 
 Any subjects identified by these methods were invited to participate in the study, receiving a letter 
to the most recent address, and those who did not refuse contact by returning a postcard, were contacted 
to arrange an appointment for a diagnostic interview. Up to several repeat appointments were scheduled 
for subjects who failed to attend the interview. Extensive efforts were made to locate individuals who were 
no longer living at the most recent listed address, including Department of Motor Vehicles records, 
telephone directories, and contacting the subjects’ parents or siblings from CHDS or Kaiser files. Mortality 
records, reverse directories, jail searches, and visits to previous addresses were also used as necessary.  
 
Ascertainment by Alameda County Behavioral Health Care Services (ABHCS)  
 Outpatients with potential BP were also ascertained by electronic record linkage between the 
CHDS and ABHCS identifiers. The ABHCS database included treatment from 1993-2009. These subjects 
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screened positive based on ICD-9 outpatient diagnoses of 295-298, excluding unipolar major depressive 
disorder. Procedures for finding and recruiting these potential subjects were similar to those described 
above for ascertainment by Kaiser. 
 
Ascertainment of CHDS birth cohort by mailed questionnaire and follow-up 
 The third method of ascertainment was initiated by letters mailed to all living mothers (N=6,971) 
and cohort members (N=13,009) with known addresses in the entire CHDS cohort (excluding families in 
which potential cases had already been identified in the Kaiser and/or ABHCS) along with a questionnaire 
on mental and physical health. This was conducted from 2009-11. Questionnaire respondents who 
reported “mental health problems” in an eligible cohort member (including the respondent him or herself) 
were contacted by a trained Kaiser study interviewer who administered the Family Interview for Genetic 
Studies (FIGS) to screen for possible BP or psychotic illness in the cohort member. If the FIGS indicated 
at least one bipolar and/or psychotic symptom (delusions/hallucinations), then the cohort member was 
considered to have screened positive, and was invited to participate in the diagnostic interview.  If the 
respondent (mother or sibling) described symptoms in a birth cohort member, the respondent was asked 
if he or she would be willing to have the study contact the affected family member about participation in 
the study. If the respondent agreed, the affected cohort member was contacted by letter and invited to 
participate.   
 
Diagnostic protocol 
 Accurate diagnosis of BP is critical to understanding its causes. A number of prior studies, as 
noted above, have suffered from poor diagnostic specificity of BP, grouping a number of illnesses into 
catch-all categories such as “affective disorders”. The current research benefits from the careful 
diagnostic assessment and inclusion of confirmed cases of BP.  
 A total of 214 subjects (48% of those ascertained) were interviewed using the Structured Clinical 
Interview for DSM-IV TR (SCID). The reasons that some subjects were not interviewed were: 100 could 
not be contacted, 80 refused or failed to keep the appointment, and 54 who could not be interviewed 
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because he or she had died, were incarcerated, permission from the physician could not be obtained, or 
because the person was too psychotic or mentally disabled.   
 Study interviewers had a minimum of a master’s degree in a mental health field and were trained 
to reliability on the SCID. DSM-IV-TR diagnoses including diagnostic qualifiers representing subtypes of 
BP were systematically assigned by consensus of three experienced clinicians (psychiatrists/Ph.D. 
psychologist), based on review of the SCID and medical records. This yielded 72 total BP cases. Among 
those interviewed, consensus diagnoses of non-BP disorders were also assigned: there were 61 cases of 
SZ and other schizophrenia spectrum disorders, 62 cases of major depressive disorders, and 19 cases 
with other diagnoses. These non-BP categories were not included in the present study. Although unipolar 
major depressive disorder was not included in the screening procedure, the diagnostic protocol enabled 
us to exclude subjects with database diagnoses of BP and/or psychotic disorders who were found instead 
to have unipolar depressive disorder in accord with structured research criteria.   
 
Ascertainment from PDS I study 
 Additional cases of BP had been ascertained through Kaiser records by an earlier study (Prenatal 
Determinants of Schizophrenia I, PDS I) were included in the present study (Susser, Schaefer et al. 
2000). Although the purpose of PDS I was to identify SZ and other schizophrenia spectrum disorder 
cases, BP cases were also diagnosed by interview in that study. The protocol for the PDS I included the 
same electronic linkages with the Kaiser inpatient, outpatient, and pharmacy databases, and utilized the 
same ICD-9 diagnostic codes (295-298).  Ascertainment covered the period from 1981-1998. The only 
other differences in the screening methods are that the PDS I did not include review of pharmacy records 
for treatment with mood stabilizers, and the PDS I included a second screening step, which involved 
psychiatrist review of abstracted data from inpatient/outpatient records for symptoms of psychosis. The 
Diagnostic Interview for Genetic Studies (DIGS), rather than the SCID, was used for interviewing potential 
subjects in the PDS I. There were 23 BP cases diagnosed in the PDS I study.  
 In total, then, 95 people with BP were diagnosed following ascertainment from all sources and 
clinical interview. 
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 After complete description of the study to the subjects, written informed consent was obtained. 
The study protocol was approved by the Institutional Review Boards of the New York State Psychiatric 
Institute and Kaiser.  
 
Control Selection 
 In order to ensure that controls would have been equally likely (as their matched cases) to be 
ascertained if they had been treated for BP in Kaiser or ABHCS, controls were matched to cases on 
membership in Kaiser (for cases ascertained through Kaiser records) or residence in Alameda County 
(for cases ascertained through ABHCS or by CHDS mailing survey) in the year the case was first treated 
as reported in the SCID. For Kaiser, membership in the plan at that time was used for control matching, 
since cohort members would have been documented in Kaiser databases if they sought care for BP. The 
DMV was used to ensure place of residence at the time of diagnosis for cases treated by ABHCS and 
those identified from the mailed survey, since these subjects would have been the population at risk for 
treatment at same time. The vast majority of the subjects who received the mailing were Alameda County 
residents. 
 Control matching criteria included: date of birth (+/- 30 days), sex, and availability of maternal 
archived sera (for serologic studies). A maximum of an 8:1 ratio of controls to cases was achieved, as it 
represented the maximum number of controls that could be successfully matched to cases on all criteria 
and to maximize statistical power. 
 Exclusion criteria (prior to matching) were: all of the CHDS cohort members who screened 
positive for potential bipolar or psychotic disorders (N=376) and siblings of those cases; potential controls 
who belonged to Kaiser at the time of case ascertainment were excluded from the control pool for cases 
identified from ABHCS or the cohort mailing; and siblings of selected controls were excluded from further 
control selection, so that all controls were independent observations, each representing a single family or 
pregnant woman.   
 This protocol yielded 754 matched controls. 
 
 




Cognitive measures in childhood: The Peabody Picture Vocabulary Test (PPVT) 
 Standardization of the PPVT for this sample was performed by converting raw scores to standard 
scores (z scores) by using the mean and standard deviation observed in each tested sample by age 
group. For the PPVT, the mean was set at 100, standard deviation of 15, as is the common practice for 
measures which estimate IQ. Once standardized, testing for ages 5 and 9-11 were combined. 
Standardized scores for the entire birth cohort tested have been calculated and normed for the cohort, 
including all cases and controls. Although standardization was done by the CHDS researchers previously, 
they normed the standardization for age, race, and gender. Because of the nature of the tests, use of 
age, race, and sex norms is unwarranted. Age variation is minimal, in fact a smaller range than is 
commonly used for norming test instruments, and race and sex can be controlled in the modeling and 
analyses if they prove to be potential confounders. Controlling for these variables in the norming makes it 
more difficult to assess whether or not they act as confounders.  
 
Cognitive measures in childhood: Raven Progressive and Colour Matrices (Raven) 
 In the CHDS, a randomly selected subset of children in the birth cohort were tested at age 5 with 
the Raven Coloured Matrices, which consists of 21 plates. Twenty-one plates were shown to each child, 
and they were asked to choose among the four options to complete the pattern in the picture. At age 9-
11, another randomly selected subset was tested, this time with the age appropriate Raven Progressive 
Matrices, which consists of 60 plates. Children are shown 60 plates and asked, for each, to select the 
pattern that completes the image from among four options. Researchers from the CHDS constructed 
standardized z-scores for each test, with a mean of 50 and standard deviation of 10. However, they used 
age, race, and sex to norm the standardization. As with the PPVT, if race or sex is found to be a potential 
confounder, it can be controlled in the analyses rather than assuming the potential effect and constructing 
norms with those variables. The original standardization sample for Coloured Matrices included 608 
children between the ages of five and 11 ½ (Raven 1956). The Progressive Matrices was normed on a 
representative British sample (Raven 1960) and no sample size is provided in the manual. The CHDS 
contains many more age cohort subjects for norming, drawn from the same Northern California region, 
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and captures the population at risk most appropriately. Moreover, the number of children administered the 
tests is substantially larger than typically obtained for norming. A total of 3,412 five year olds were 
assessed with the Raven, and 3,737 children at ages 9-11. 
 For these analyses, cohort norms for the Raven have been calculated using a mean set at 0 and 
a standard deviation of 1. After converting into standard units based on the proportion correct, the results 
have been combined for age 5 and ages 9-11 such that the entire cohort can be analyzed at once. 
  
Analytic method for testing the association between childhood cognitive performance and BP 
 Fifty cases and 215 matched controls were tested in childhood. None of those tested at age 5 
were also tested at ages 9-11 in this subset of the birth cohort. These subjects were randomly selected 
for testing in childhood from the full birth cohort. As a result of standardizing the scoring on the different 
instruments used for assessment, differences between groups will be observed by standard deviation 
units. This study has sufficient power to detect a large association (OR = 2.8, power of .8 and p = .05),  
 The relationship between cognition and BP was assessed using conditional logistic regression. It 
was hypothesized that cognition may be directly related to risk of BP. If it is, mediational analyses will be 
undertaken to assess whether cognition mediates the relationship between T. gondii, oxytocin and BP. 
The central role of cognition in SZ, and potentially in BP, suggests that it may be one of the mechanisms 
that leads to later onset of psychotic illnesses. Mediation was analyzed by testing the associations of 
each exposure with BP directly, then testing the association with cognition as a potential mediator in the 
model. Analyses will compare changes in the beta estimate of the models, assuming no unmeasured 
confounding or effect modification (Baron and Kenny 1986). It is not expected that cognition would fully 
mediate the relationship, but a priori, a ten percent change in beta estimate was considered meaningful. 
 Maternal age (<35 [reference], ≥35), maternal ethnicity (Caucasian [reference], African American, 
other), maternal educational achievement (defined as maternal education: <high school, high school only 
[reference], some college/college graduate), parity, gestational age (number of days after last menstrual 
period), and maternal psychiatric history are considered as potential confounding variables. Each 
covariate's association with BP and with cognition was tested for significance of a possible association. 
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Fetal hypoxia was considered as a potential confounder but no reliable measure of it was available in 
these data. 
 
Analytic method for testing the association between prenatal/perinatal exposures and childhood cognition  
 Next, each of the prenatal and perinatal exposures (gestational influenza, T. gondii, and oxytocin 
to induce labor during pregnancy), as documented in the CHDS contemporaneous to birth, was analyzed 
for a potential effect on childhood cognition. Influenza and oxytocin to induce labor are documented in 
medical charts of the CHDS for each birth. These analyses investigate whether induced labor or 
gestational influenza are associated with cognitive performance on the childhood measures. In total, at 
ages 5 or 9-11, 7096 children were given the Raven and 7039 were given the PPVT. Gestational 
influenza and oxytocin are tested in the full birth cohort because those conditions were noted in the 
medical records. Thus, whether those conditions have an effect on cognition in childhood can be 
ascertained. The association between influenza and BP has been demonstrated in previous studies in 
this birth cohort (Parboosing, Bao et al. 2013, Canetta, Bao et al. 2014), as noted above, but the 
association or role of cognition in that association has not yet been tested.  
 
Analytic method for testing the association between gestational influenza and childhood cognition 
 Maternal influenza during pregnancy was coded in the CHDS for nearly every birth, permitting 
assessment of cognition as an outcome for all those children tested in childhood. The literature review did 
not uncover a prior study of the relationship between maternal influenza and childhood cognition in a birth 
cohort. Moreover, documentation of influenza was obtained at birth, not retrospectively from maternal 
interview, as part of the medical care provided to all the women in the cohort. This significantly improves 
on previous research by eliminating recall biases. 
 GEE models were used because of siblings in the birth cohort. The exchangeable correlation 
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Analytic method for testing the association between Toxoplasmosis (T. gondii) and childhood cognition 
 The CHDS aimed to obtain maternal serum for each pregnancy during each trimester. At each 
blood draw, 30 cc were collected and spun, dividing the sera into four aliquots of approximately 2 cc 
each. The samples were transferred to glass vials and stored frozen at -20 degrees since being obtained. 
One-two cc of maternal sera were provided for each time point during pregnancy for each case and 
control. These serum samples have been successfully analyzed now for a number of biomarkers, 
including for T. gondii. Biomarker evidence, obtained prospectively, is the gold standard for assessing the 
exposure and ensuring pre-birth maternal exposure. 
 The T. gondii assays were performed in the Toxoplasma Serology Laboratory at the Palo Alto 
Medical Foundation Research Institute, which is the T. gondii reference laboratory for the US (Montoya 
2002). Three assays were used. The first two concern the assessment of T. gondii IgG antibody titer. 
Samples were screened for the presence of IgG antibody titer and then the Sabin-Feldman dye test 
(Sabin and Feldman 1948) was performed in the samples that screened positive. T. gondii IgM antibody 
was also assayed, which is indicative of recent infection, using the double sandwich enzyme-linked 
immunosorbent test (IgM-ELISA). The seroprevalence of IgG antibody was 22/123 (17.9%) in controls. 
This value is similar to the 17.5% seroprevalence found in a large previous study of T. gondii in 
reproductive-aged women (Jones, Kruszon-Moran et al. 2001). None of the control serum samples tested 
by ELISA were positive for T. gondii IgM antibody. This was not unexpected, as T. gondii IgM antibody is 
indicative of active infection within 2 months of the blood draw, which is unlikely given the low incidence 
of toxoplasmosis during this time frame (Remington 2011).  
 For the primary analysis, T. gondii IgG for the last serum sample drawn for each pregnancy (late 
third trimester/perinatal) was analyzed. This replicates the methods used in the PDS study of T. gondii 
and SZ (Brown, Schaefer et al. 2005). The third trimester/perinatal period of gestation provides the 
greatest opportunity to detect T. gondii infection if it occurred at any time during pregnancy because even 
an infection that occurred early in pregnancy will result in elevated IgG antibodies for many months or 
years following infection (Remington 2011).  
 The dye test IgG titers will be classified into three groups: negative (<1:16) (reference), moderate 
titer (1:16-1:64), and high titer (≥1:128). We hypothesized that the high IgG titer group would have worse 
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performance on cognitive testing in childhood. The hypothesis is tested by conditional logistic regression 
in the nested case control sample. 
 
Analytic method for testing the association between in utero exposure to oxytocin and childhood cognition 
 Oxytocin administration to induce labor was contemporaneously documented in medical charts in 
the CHDS. The CHDS noted oxytocin in four separate fields which have been combined to construct a 
dichotomized variable: oxytocin versus no oxytocin. The analyses will consider whether oxytocin 
exposure during maternal labor is associated with performance on the Raven and the PPVT. 
 GEE models were used because of siblings in the birth cohort. The exchangeable correlation 
structure, which produced the smallest QIC (quasi Akaike Information Criterion) value, is reported. 
 
Results  
Results for childhood cognition and BP 
 Fifty people who later developed BP and 215 matched controls underwent cognitive assessments 
during childhood. Table 11 presents the summary data on the childhood testing. On average, those who 
later develop BP had a higher PPVT score than those who did not, but also a lower Raven score. The 
range of scores for cases on the PPVT was much wider than for cases, with a longer right tail, indicating 
some very high scores compared to controls. The range of scores of the Raven, in contrast, is narrower 
for those who later develop BP, with a truncated right tail.  
 
Table 11: Summary data for childhood cognitive testing   
  Mean Standard 
Deviation 
Minimum Maximum 
PPVT Case (N = 50) 103.1 14.69 53.93 145.47 
 Control (N = 213) 100.1 12.45 73.78 127.8 
Raven Case (N = 50) 0.0237 0.85 -2.327 1.62 
 Control (N = 214) 0.0254 0.996 -2.327 2.33 
 
 Using conditional logistic regression for the matched case-controls sets, childhood cognition is 
not associated with later life BP (Table 12). Neither test was significantly associated with BP and the 
effect size is negligible. 
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PPVT 1.016 (0.992, 1.041) 
Raven 1.015 (0.732, 1.408) 
 
 In secondary analyses, the association of childhood cognition and BP with and without psychotic 
features was tested (Table 13). Dividing BP into these two types did not change the lack of association 
between childhood cognition and later BP. 
 







1.047 (0.629, 1.742) 
Raven, without 
psychotic features 
0.994 (0.649, 1.522) 
PPVT, psychotic 
features 
1.012 (0.978, 1.048) 
PPVT, without psychotic 
features 
1.019 (0.986, 1.053) 
 
 Post hoc tests for possible negative confounding by gestational age, maternal race, and maternal 
education confirmed that these covariates are not confounders, and did not alter the lack of association 
observed for childhood cognition and BP.  
 
Discussion of childhood cognition and BP 
 These results of the relationship between premorbid cognition and later onset BP are consistent 
with previously published studies, but those studies have shown both better and worse performance 
during the premorbid period (Meyer, Carlson et al. 2004, Osler, Lawlor et al. 2007, Koenen, Moffitt et al. 
2009, Sorensen, Saebye et al. 2012, MacCabe, Wicks et al. 2013). Those who later develop BP perform 
slightly better than controls on the PPVT and also have a wider spread of scores, with both the high and 
low scores beyond those obtained by controls. On the Raven, where those who later develop BP have a 
slightly lower mean, the minimum scores are equivalent for cases and controls but the maximum scores 
obtained are truncated for cases. Thus, people who later develop BP perform on average better on the 
global measure of cognition (PPVT) and the same or slightly weaker on visuospatial reasoning. The 
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consistency with other research serves as a validity check despite the sample being underpowered to 
reach conclusions.  
 It is also possible that the lack of association between childhood cognition and later BP may be 
explained by a number of factors specific to this birth cohort and these test instruments, or it may be a 
reflection of the true lack of association in BP, which would distinguish BP from SZ. The expected size of 
premorbid cognitive deficit has recently been reported for a number of cognitive domains to range 
between none and an effect size of approximately .8 for verbal learning and delayed visual and verbal 
memory (Kurtz and Gerraty 2009). Relevant for comparison to this study, the visual spatial domain was 
less impaired (Cohen's d = .55) in that meta-analysis (Kurtz and Gerraty 2009). Neither of the two test 
instruments in the CHDS are likely to assess the areas of impairment most observed in BP. Kremen et al 
observed a difference on the PPVT with fewer cases (n = 10) in this same cohort for those who later 
developed SZ (Kremen, Vinogradov et al. 2010), supporting the hypothesis that a more generalized, 
global impairment is observed in premorbid SZ compared to premorbid BP. The finding may reflect a true 
lack of association between premorbid cognition and BP as well. The evidence to date is mixed, with 
support for deficits in some specific cognitive domains, and strengths in others. The variability of cognitive 
performance in premorbid BP may make cognition a less useful early marker of disease as compared to 
that observed in SZ.  
 Overall, this finding does not support the neurodevelopmental hypothesis of BP. 
 
Results for gestational influenza and childhood cognition 
 Exposure to maternal influenza during gestation is not associated with childhood cognition (Table 
14). Using GEE models and reporting the exchangeable correlation, neither the PPVT nor the Raven is 
significantly associated with gestational influenza. The direction of the result is towards worse 
performance on childhood testing for those exposed, but it is a small and non-significant effect.  
 





PPVT (N = 6609) -0.54 (-2.18, 1.78) 
Raven (N = 6667) -0.0495 (-0.18, 0.083) 
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Discussion of gestational influenza 
 Gestational influenza is not associated with cognitive impairment in childhood. The sample size is 
large, meaning there is sufficient power to observe an effect if one exists. This study offers a direct test of 
the findings from observational studies. Those observational studies suggested worse performance in 
those who were exposed. However, the lack of direct measures of the exposure (with estimates of 
exposure based on time of birth and high point of circulation of the virus) make the association difficult to 
determine and requires parsing from a number of other exposures that might confound the association. 
Here, the medical record notation of maternal influenza during pregnancy provides a very good, 
prospectively documented record of exposure, and with this clear measure, no association is observed. 
 It remains possible that direct testing of the maternal sera would provide a better and more 
precise measure of maternal influenza, as it remains possible that medical staff noted any viral infection 
as influenza when it may have been another virus.  
 
Results for T. gondii and childhood cognition 
 In this birth cohort, T. gondii is not associated with childhood cognitive performance (Table 15). 
None of the titer levels of maternal sera are associated with offspring cognition. Post-hoc analyses of a 
possible association between T. gondii titer and BP with psychotic features was also not significant. 
  
Table 15: Gestational T. gondii titers and childhood cognition 









PPVT (N = 250) Moderate 
(1:16-1:64) 
0.07 (0.52, 2.35) 0.8 
 High 
(1:128-1:512) 
0.2 (0.49, 1.56) 0.66 
Raven (N = 146) Moderate 
(1:16-1:64 
0.24 (0.32, 6.60) 0.63 
 High 
(1:128-1:512) 




 The prospectively obtained, frozen serum based measurement of T. gondii in this cohort makes 
these data unique. T. gondii is not associated with BP or childhood cognition, unlike SZ, where it is 
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associated with both (Brown, Schaefer et al. 2005, Brown, Vinogradov et al. 2009). This is consistent with 
a previous finding (Mortensen, Pedersen et al. 2011). This finding suggests that T. gondii, observed in 
patient samples, is not associated with BP, and does not provide support for the neurodevelopmental 
hypothesis for BP. It also suggests that at least some prenatal exposures could be specific to SZ and BP, 
rather than the two conditions having similar causes but differing phenotypes. 
 
Results for oxytocin to induce labor and childhood cognition 
 In bivariate analyses to test for potential confounders (Table 16), gestational age, maternal 
education, and maternal race were each significantly associated with oxytocin and cognition.  
 
Table 16: Bivariate analyses of covariates and oxytocin 
 Parameter 
Estimate 
95% CI Pr > |Z| 
Maternal race: 
African-American 
-0.67 (-0.72, -0.61) <.0001 
Maternal race:  
other 
-0.04 (-0.13, 0.05) 0.395 
Maternal education: HS 
graduate 
-0.287 (-0.35, -0.22) <.0001 
Maternal education: some 
college or more 
0.396 (0.34, 0.45) <.0001 
Gestational age 0.004 (0.003, 0.006) <.0001 
Maternal psychiatric 
history, any 
-0.046 (-0.122, 0.29) 0.23 
Notes: White is the reference group for maternal race; Less than high school is the reference group for 
maternal education. Gestational age, maternal race, and maternal education were tested in bivariate 
models with only oxytocin. 
 
 First, an unadjusted model (Table 17) to test the association between oxytocin and childhood 
cognitive performance found that oxytocin given to induce labor is significantly associated with a reduced 
score of .14 (CI: -0.26, -0.03, p = .02) standard deviation units on the Raven (N = 7017). It is non-
significantly associated with a reduced score of .45 (CI: -2.12, 1.23, p = 0.6) standard deviation units on 
the PPVT (N = 6959).  
 
Table 17: Unadjusted association between oxytocin and childhood cognitive tests 
 Parameter Estimate 95% CI  Pr > |Z| 
Raven (N = 7017) - 0.14 (-0.26, -0.03) 0.02 
PPVT (N = 6959) - 0.45 (-2.12, -1.23) 0.6 
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 In the fully adjusted model, oxytocin remains significantly related to worse Raven performance. 
This model (Table 18) controls for the covariates which may confound the relationship. The effect size for 
the reduced score on the Raven is relatively the same as the unadjusted model.  
Table 18: Fully adjusted association between oxytocin and childhood Raven 
 Parameter Estimate 95% CI Pr > |Z| 
Intercept -0.55 (-0.96, -0.14) 0.0088 
Oxytocin -0.14 (-0.26, -0.03) 0.0141 
Gestational age 0.002 (0.001, 0.004) 0.004 
Maternal psychiatric 
history 
-0.019 (-0.09, 0.06) 0.618 
Maternal education: 
HS graduate 
-0.20 (-0.27, -0.14) <.0001 
Maternal education: 
some college or more 
0.38 (0.33, 0.43) <.0001 
Maternal race: 
African-American 
-0.61 (-0.66, -0.55) <.0001 
Maternal race: 
other 




 This is the first time that oxytocin to induce labor has been evaluated for a possible effect on 
childhood cognition in a longitudinally followed, prospective birth cohort. The finding that the performance 
on the Raven is significantly worse for those who are induced, but that the PPVT is not, may suggest a 
specific mechanism or neural region which is affected, but further testing would be needed to assess that 
hypothesis. It is worth noting that oxytocin has a negative effect on cognitive performance but gestational 
age has a positive effect (longer gestation is associated with better performance). This suggests some 
specificity related to oxytocin, and that oxytocin is not simply a marker for longer gestational age. 
 
Conclusion 
 Childhood cognition was not associated with BP, although the small but better performance on 
the PPVT, and the slightly worse performance on the Raven, is generally consistent with other research. 
The finding that oxytocin to induce labor is associated with worse cognitive performance on the Raven 
suggests a need for further research on the effects of oxytocin. None of the other prenatal and perinatal 
exposures were associated with childhood cognition. 
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 As noted, the neuropsychological battery used by the CHDS focused on global functional ability 
and school readiness. As such, it is not surprising that no association with BP is observed on these 
premorbid test instruments. In considering whether these data support the neurodevelopmental 
hypothesis of BP, they do not particularly. Yet, the comparison of mean scores and the distribution of 
scores is suggestive of a possible premorbid cognitive pattern observed in other studies: slightly higher 
scores on global measures, with both very high and very low scores; as well as slightly lower scores on 
more specific domain measures, as reflected here by the range on the Raven. Larger samples may have 
enough power to determine whether these small differences are premorbid to BP or normal population 
variation. The two tests in the CHDS battery do not assess some of the areas of impaired performance 
during the premorbid period such as executive functioning and verbal memory. Future studies would 
ideally have additional measures which specifically assess the domains hypothesized to differ during the 
premorbid period of BP.  
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Conclusions, Strengths, and Limitations 
 The clearest strength of this research lies in the quality of the prospective birth cohort; the 
prospectively obtained data, including serologically obtained biomarkers and medical record 
maintenance; and the research diagnosis for all potential case subjects. The long follow-up period (1981-
2009) means that cases have been identified at the point of first treatment, allowing for comparison of 
incident cases. This allows for time at risk between the exposed and unexposed to be directly 
comparable. Second, the prospective nature of this study and the continuous follow-up means that data 
are not dependent on maternal recall or other retrospective techniques, increasing accuracy. Third, 
although loss to follow-up and the moderate response rate could induce bias, it is expected to be non-
differential. Although this cannot be directly tested, every effort to assess the consequences of the loss to 
follow up was undertaken using sensitivity analyses. Fourth, case identification, as described above, used 
research criteria applied by direct assessment with structured, standardized research instruments (the 
Structured Clinical Interview for DSM-IV (SCID) for BP and the Diagnostic Interview for Genetic Studies 
for Schizophrenia), thereby reducing misclassification. The DIGS was developed from the SCID, and is 
also based on DSM-IV criteria, and thus the two interviewers are highly comparable with one another. 
 There are also limitations to this study: first, despite being substantially larger than most studies 
of BP, a number of potential cases could not be enrolled because they could not be located or refused or 
failed to participate. Thus, as with all longitudinal studies, loss to follow-up potentially biases this study. 
The ascertainment process was conducted to capture as many potential cases as possible and every 
effort was made to locate and interview each. While few meaningful demographic differences are 
observed, it is not possible to calculate the extent to which bias from loss to follow-up might be having an 
effect or the direction of that hypothetical effect. The sensitivity analyses suggest that the effect of this 
loss to follow-up was negligible. Those calculations are based on information about the exposed in the full 
cohort, allowing for a direct assessment of potential bias in ascertainment. Further, the prevalence of BP 
cases identified in this study comports with the national and international rates (Merikangas, Akiskal et al. 
2007, Merikangas, Jin et al. 2011), providing some confidence that few cases have been missed.  
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 Second, because of concern that inclusion of potential case siblings would mean correlation 
between cases and/or between cases and controls, potential case subject siblings were excluded from 
being controls. This may have introduced bias in making the controls healthier than they should have 
been. Third, for the cognitive testing, a random sample of the cohort was tested at ages 5 and 9-11, 
meaning that some of the current study subjects were not tested in childhood. The random selection of 
subjects for testing makes this unlikely to bias results, but it does reduce the number of subjects in the 
study, limiting power. Further, the limited testing battery which focused on global strengths and 
weaknesses is likely to underestimate the more specific cognitive deficits that have been reported in BP, 
possibly explaining the lack of association observed. 
 Taken as a whole, the findings suggest support for the neurodevelopmental hypothesis of BP 
being both similar to and different from the course observed in SZ. In the largest view, these data lend 
support to some specificity in the risks for BP, and provide further evidence for risks which are observed 
in SZ not being similarly associated with BP. In the narrowest view, one specific potential risk is observed 
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